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Abstract
We have reported that a microbiome-derived Toll-like receptor 2 (TLR2) ligand, Lipid 654
(L654), is decreased in the circulation of MS patients. This led us to ask 1) why is a TLR ligand
low in an inflammatory disease like MS, 2) what are the properties of L654 that might be
biologically relevant and 3) can serum L654 be used as a biomarker for MS disease status or
activity?

We proposed that microbiome products routinely accessing the circulation maintain a state of
immune tolerance. TLR tolerance is a mechanism that, through low-level, tonic ligation of TLRs,
establishes the threshold and magnitude of TLR signaling. Therefore, we proposed that a loss of
micribiome-mediated TLR tolerance plays a role in the pathogenesis of MS. As proof of concept
we asked whether low-level administration of a TLR2 ligand in EAE could induce TLR2tolerance and attenuate disease. Indeed, administration of a cannonical TLR2 ligand and L654
both induced TLR2-tolerance and attenuated EAE. Additionally, suggesting this is a normal
mechanism of immune tolerance that is deficient in MS, we showed that monocytes from active
MS patients are hyper-responsive to a TLR2 ligand. Next, as L654 is a newly described
molecule, we posited that studying the chemical and biological properties of L654 would provide
insight into its role in MS. We found that L654 exists in multiple isoforms, and there is
preferential hydrolysis of L654 by Phospholipase A2 (PLA2) for one isoform. We also have data
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suggesting that the ratio of isoforms determines the TLR2 activity. Additionally, there is greater
breakdown of L654 in serum of MS patients compared to controls, suggesting a potential role for
PLA2 in MS. Importantly, we found serum L654 levels may correlate with MS disease activity.

Overall, our results suggest that systemic exposure to low-level microbiome products can inhibit
CNS autoimmunity and that restoring this microbiome function in patients with MS may offer a
new approach to treating this autoimmune disease. Additionally, the relationship between PLA2
and L654 may provide insight into why serum L654 is lower in MS. Lastly, L654 has potential
to be utilized as a serum biomarker for MS.
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Chapter 1 Introduction
General Comments
In the study of autoimmune disease, one must always be considering both the inflammatory and
regulatory aspects of each question posed. Immune homeostasis is only maintained in a state of
fine balance between inflammation and immune regulation. This balance can be tipped when
necessary, i.e. to fight infection, towards inflammation; yet, when inflammation is elicited, so
must immunoregulatory mechanisms be elicited to return the balance to a level, steady-state after
the threat is cleared. When immunoregulatory mechanisms are not elicited or when inflammation
is too great to control, autoimmunity can ensue.

Multiple sclerosis (MS) is an autoimmune disease of the central nervous system that results in
relapsing-remitting or progressive paralysis and severe debilitation. MS is prevalent, affecting
near 1 in 1000 people in the United States alone and current treatments are unable to prevent the
long-term progression of disease. The mouse model used to study MS is experimental
autoimmune encephalomyelitis (EAE). Various models exist and the differences and benefits to
each can guide their usage as models to study the question of interest.

Understanding the relationship between autoimmunity and immune regulation is critical when
delving into a disease model of autoimmunity, and all findings must be interpreted with this in
mind. For example, in an active model of Experimental autoimmune encephalomyelitis (EAE), it
has been shown that CD4+FoxP3- T effector cells (Teffs) peak in the central nervous system
(CNS) 3 days before the clinical disease peaks and then rapidly decline while a regulatory cell
type, CD4+FoxP3+ T regulatory cells (Tregs) peaked about 9 days before the clinical disease
1

peaks and then are maintained at that level through recovery(1). Therefore, it may be misleading
that a strong disease which peaks early may have an increased Treg to Teff ratio compared to a
delayed or less severe disease that has not yet reached its peak (Figure 1-1). In the study of
autoimmunity, we are constantly addressing both the pathogenic and regulatory cell types
involved, utilizing frequencies or ratios of regulatory cells to effector cells as the most important
read-out, when interpreted correctly.

To introduce the three chapters of my thesis work, I will discuss mechanisms of both
autoimmunity and immune regulation in MS and EAE. Within this context, I will also discuss
toll-like receptors (TLRs) and their ligands, pathogen-associated molecular patterns (PAMPS).
We are specifically focused on those PAMPS derived from the microbiome and how they are
able to interact with the systemic immune response and regulate the balance between
autoimmunity and immune regulation.

Multiple sclerosis
The requirements for a diagnosis of multiple sclerosis is defined by the McDonald Criteria,
which utilizes physical exam and magnetic resonance imaging (MRI) to define multiple sclerotic
lesions in the white and grey matter of the CNS that are separated in location and in time(2).
Though controversial, some argue that the utilization of testing for oligoclonal bands in the
cerebral spinal fluid (CSF) is downplayed by the McDonald Criteria and may aid in the diagnosis
of MS in certain situations(3). Currently, there is no blood test to aid in the early or confirmatory
diagnosis of MS.
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The etiology of MS is unknown, though there is evidence for both a genetic and an
environmental contribution. Genome-wide association (GWAS) studies have shown that the
human leukocyte antigen (HLA) locus is the key susceptibility locus, implicating the
HLADRB1*15.01 haplotype as carrying the largest risk in MS. However, genetics has a whole,
plays only a small role in susceptibility to MS(4). Environmental risk factors that have been
implicated include living in a geographical high-latitude before age 15, low Vitamin D, close
living quarters to someone with MS, hygiene, cigarette smoking, female gender, young adult age
and various infectious agents(4). As of yet, there is no evidence of a role for the microbiome in
MS risk.

MS can manifest in various clinical forms. There are four major clinical subtypes recognized:
Relapsing-Remitting MS (RRMS), Secondary Progressive MS (SPMS), Primary Progressive MS
(PPMS), and Progressive Relapsing MS (PRMS). Near 87% of patients with MS are diagnosed
with RRMS(5). Patients with RRMS have “flares” of disease followed by periods of remission.
Patients with SPMS begin with RRMS and then move to a progressive phenotype with no
remissions. Most RRMS patients eventually transition into SPMS. Patients with PPMS are those
that have had progressive disease from the time of diagnosis. This subtype is often argued to be a
completely different disease than RRMS, with dissimilar pathology that requires distinct
treatments. Finally, PRMS resembles PPMS but with superimposed acute flares. Symptoms of
MS are heterogeneous, as are the location and severity of lesions, and can include visual
changes, weakness, fatigue, incoordination, sensory loss, changes in bladder and bowel function,
cognitive changes, mood disturbances, and varying levels of motor paralysis.
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Most of what is thought to be true of the pathogenesis of MS has been determined using the
mouse model, EAE. However, it has been shown that inflammatory infiltrate across the bloodbrain barrier (BBB) promotes inflammation, demyelination, gliosis and neuroaxonal
degeneration leading to disruption of neuronal signaling in patients with MS(6). In MS, T
lymphocytes appear in lesions early, but lesions are predominantly infiltrated with macrophages,
followed by CD8+ T cells and fewer CD4+ T cells. B cells and Plasma cells can also be found in
low numbers. The disease is thought to be of autoimmune origin, initiated by autoreactive
lymphocytes responding to self-antigens in the CNS (Figure 1-2).

Current treatments target peripheral immune cells to reduce activity and entry into the CNS.
These therapies are broadly immunosuppressive and so are associated with unwanted side
effects. As of now, treatments have been shown to decrease the frequency of relapse, but do not
halt the overall progression of the disease. This has elicited a theory of two separate processes
responsible for relapses and chronic progression of the disease. This would mean that RRMS
patients might not really transition into SPMS, but that now the progression is more evident at
this chronic stage. This theory also coincides with the current inability to find an efficacious
treatment for PPMS. As it stands now, treatments are able to decrease relapses but not the
chronic progression of disease in any subtype of MS(6).

Experimental Autoimmune Encephalomyelitis
EAE is the mouse model of MS used most commonly. EAE does not directly reflect the
pathogenesis seen in MS. For example, most EAE models show inflammation focused in the
spinal cord, where MS is dominated by mostly brain inflammation. Similarly, the major T cell
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infiltrating lesions in EAE are CD4+ T cells, where MS has CD8+ T cells dominating. Some
drugs, such as anti-TNFα, tested first in EAE have not always translated to MS, and some
researches argue that this model is not useful(7). Conversely, the effective MS drug natalizumab
was implemented clinically directly following the success of blocking α4β1 integrin in EAE.
Like any animal model of human disease, if used correctly then EAE can be used to gain
valuable insight into MS(8).

There are variations to this model, each with its own pros and cons. The active disease model of
EAE in C57BL/6 mice is induced using Complete Freund’s Adjuvant (CFA) emulsified with
myelin oligodendrocyte glycoprotein (MOG35–55) peptide and pertussis toxin. This model proves
that in mice, pre-existing myelin-reactive T cells are present in the periphery, and are
functionally capable of mounting an immune response when cognate antigen is seen in the
context of an adjuvant. In MS but also in healthy individuals, circulating CD4+ T cells have been
shown to be reactive to MOG, proteolipid protein (PLP) and myelin basic protein (MBP)(9). An
active model of EAE like this is uniquely useful for studying the initiation and priming stage of
MS (Figure 1-3). Another commonly used model is the T cell adoptive transfer model in SJL/J
mice. In this model, SJL/J mice are immunized with CFA and PLP139-151. The draining lymph
node is harvested and the cells are re-stimulated with PLP139-151 in culture before being
transferred into a naïve SJL/J mouse. This model is beneficial for a few reasons. For one, when
studying the recipient mice this model is free from adjuvant. This makes studying the effect of
PAMPs or the role of toll-like receptors (TLRs) in EAE much easier. Additionally, this model
can manifest a relapsing-remitting phenotype allowing researches to study that aspect of MS.
Epitope spreading has been shown to occur in MS and EAE, and is theorized to account for the
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relapses seen in MS and in relapsing-remitting models of EAE(10). After each flare, tissue
damage in the CNS exposes new auto-antigens that were previously masked due to the immune
privileged status of the CNS. Epitope spreading can be studied in this model(11).

What we have learned of the pathogenesis of MS through studying EAE is complex and still not
fully understood. In general for either model described above, after activated T cells are present
they traffic to the CNS and cross the BBB. In the CNS, either resident antigen presenting cells
(APCs) or APCs that have trafficked into the CNS are responsible for re-activating the
autoreactive T cells. CD4+ T helper cells categorized as Th1 and Th17 cells are those thought to
be most pathogenic in this model. Th1 cells are produced when IL-12 is present, which causes
upregulation of the transcription factor T-bet (responsible for the Th1 phenotype). Th17 cells are
produced when IL-6 and TGF𝛽 are present, which cause the upregulation of ROR𝛾T
(responsible for the Th17 phenotype). Upon re-activation, these two cell types can secrete
granulocyte macrophage colony-stimulating factor (GM-CSF), which has been shown to have
pro-inflammatory effects including increasing APC maturation and, along with the chemokine
(C-C motif) ligand CCL2, has been shown to increase the migration of inflammatory monocytes
from the bone marrow to the CNS(12, 13). This leads to recruitment of monocyte into the CNS
as well as activation of bystander APCs. The culmination of cytokine secretion by effector T
cells results in the release of reactive oxygen species from inflammatory monocytes, tissue
resident macrophages, microglial cells, and recruited neutrophils. This leads to myelin
destruction, gliosis, axonal degeneration, and eventually paralysis. Though this is the generally
accepted schema, it is also fraught with complexities, contradictory studies, and an incomplete
understanding of the many key players.
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Autoimmunity in MS
As described above, autoimmunity occurs when there is a tip towards inflammation in the
balance with immunoregulation. This can either be due to an increase in a propensity for
inflammation or a decrease in the functioning of immunoregulatory mechanisms. In all
likelihood, both are involved when autoimmunity ensues. In MS, GWAS studies have implicated
genes encoding proteins involved in inflammation such as Cbl –b, interferons, interleukin-2 and
NFκB(14). Yet, there are multiple mechanisms of immunoregulation and tolerance that are
normally in place to avoid autoimmunity even in the face of increased inflammation. Central
tolerance occurs during the development of the immune system, to delete autoreactive T cells
from the immune repertoire(15). However, because autoreactive T cells have been found in both
mice and humans we know that central tolerance does not delete autoreactive T cells with 100%
efficiency(16). Still, peripheral mechanisms of tolerance are in place to prevent any autoreactive
T cells from mounting an immune response to self should autoreactive T cells escape the thymus.
Among these mechanisms are the requirement for T cell co-stimulation during activation by
APCs, which in turn requires stimulation by PAMPS, as well as various regulatory cell subsets
that dampen immune responses toward self-antigens. Molecular mimicry is the theory of
initiation of autoimmunity through activation of cross-reactive T cells by a viral or bacterial
pathogen that resembles a self-antigen. In MS, infectious agents such as Epstein-barr virus have
been implicated, yet current data is controversial or not fully understood(6). This model falls
under the “outside-in” theory of disease initiation in MS. On the contrary, others believe that the
primary injury occurs in the CNS, exposing previously immune-privileged self-antigens to the
immune system (“inside-out”)(6). Whether the initiation of MS occurs this way, it has been
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shown that once an attack on the CNS occurs and tissue damage results, there is exposure to new
self-antigens that were previously hidden from the immune system. The recruitment of immune
cells to this location during this time allows for immune responses to new self-antigens to be
mounted. As this occurs, the epitope recognized by the majority of autoreactive T and B cells
changes over time in MS and EAE, referred to as epitope spreading(10, 11).

Immune Regulation in MS
As mentioned above, various regulatory mechanisms are in place to prevent autoimmunity in the
face of inflammation. Regulatory T cells including forkhead box P3 (FoxP3) expressing CD4+ T
cells and interleukin-10 (IL-10) producing CD4+FoxP3- cells (TR1s) are capable of suppressing
autoreactive T cells and inflammation. These cells have been shown to be important in the
regulation of EAE and have been implicated as defective in MS(17-19). Additionally, 𝑦𝛿 T cells,
B1 regulatory B cells, and tolerogenic DCs may also mediate suppression through IL-10, which
has been implicated in protecting against EAE(20-22). iNKT cells can mediate suppression of a
Th1-mediated disease, such as EAE and MS, by skewing the effector phenotype towards a Th2dominated response. This is thought to occur through iNKT cell secretion of IL-4 or CCL2(23).
iNKT cells have been implicated in the protection from EAE(24, 25). Lastly, IFN𝛽 has also been
shown to be important in protection from EAE and is a cornerstone treatment for MS(26, 27).

The microbiome and the systemic immune response in MS and EAE
The microbiome has been shown to both regulate and promote systemic autoimmunity in various
disease models, but through mechanisms that remain unidentified(28). Although the role of the
microbiome in MS remains unknown, it has been shown to be important in the pathogenesis of
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disease in EAE, as EAE is attenuated in germ-free mice(29). Conversely, microbial products
have also been shown to suppress EAE disease severity (30, 31). Importantly however, low
levels of tonic Toll-like receptor (TLR) signaling, through ligation with microbial products, has
been shown to play a role in promoting immune cell development and maintaining bone marrow
homeostasis(32, 33). The mechanisms by which the microbiome naturally modulates the
systemic immune response to maintain homeostasis and how it can affect the balance between
autoimmunity and immunoregulation in MS and EAE remain unknown.

A microbome-derived TLR ligand is lower in the serum of MS patients
We have previously characterized the structure of a novel human and mouse TLR2 agonist,
termed L654, which is produced by bacteria of the phlyum Bacteroidetes. These bacteria make
up about 30% of the normal flora in the gastrointestinal tract(34). This microbiome-produced
TLR2 ligand was found to be present in the systemic circulation of healthy humans(35), and
therefore, it has the potential to mediate effects of the microbiome on the systemic immune
system. Our laboratory has shown that serum levels of L654 are significantly lower in MS
patients compared to both healthy controls and patients with Alzheimer’s disease (Figure 15)(35). Therefore, we hypothesize that in healthy individuals L654 and other microbiomederived TLR ligands may play a role in maintaining immune homeostasis through low-level,
tonic ligation. When low in serum of MS patients, this mechanism of immune regulation is
removed, and may contribute to tipping the balance of immune homeostasis towards
inflammation and autoimmunity. A lack of such microbiome-derived TLR ligands in human sera
may represent an environmental contributor in the etiology of MS.

9

One mechanism through which tonic TLR signaling can lead to immune regulation is through
TLR tolerance. While TLR ligands first promote downstream signaling of the receptor, repeated
ligation can result in negative feedback leading to signal dampening, or a state of tolerance, that
prevents subsequent ligations from signaling at normal magnitude. If a defect in TLR tolerance is
contributing to MS and EAE, then we hypothesize that 1) TLRs must play a role in the
pathogenesis of these diseases, and 2) a hyper-responsiveness to TLR ligands is present in
patients with MS. While I address these hypotheses in my thesis work, we utilize L654 as a
representative microbiome-derived TLR ligand, and therefore explored the role of TLR2 in MS
and EAE.

The role of TLR2 in MS and EAE
Toll-like receptor 2 (TLR2) expression has been shown to be upregulated on oligodendrocytes
and potentially on peripheral blood mononuclear cells (PBMCs) of MS patients(36, 37). In
EAE, TLR2 expression is upregulated in the spinal cord(38). Despite this increase in expression,
the role of TLR2 has remained unclear. The disease severity of TLR2-deficient mice compared
to wildtype (WT) mice in various EAE models is controversial. TLR2-deficient mice have been
variably shown to develop comparable disease severity, attenuated disease severity, or no disease
at all in both active disease and adoptive transfer models of EAE(38-42). Though controversial,
TLR2 dependence in an adoptive transfer model of EAE may suggest either endogenous or
exogenous TLR2 ligands are involved in the disease pathogenesis. Moreover, TLR2 deficient
mice have also been shown to have a decreased number of systemic T helper 17 (Th17) T cells, a
cell implicated in the disease pathogenesis of EAE, lending further support for a potential role of
TLR2 in promoting EAE(41).
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In stark contrast to the potential requirement for TLR2 in the EAE disease process, other studies
have shown that TLR2 ligands can attenuate or inhibit EAE. When administered over
consecutive days to mice during EAE development, Polysaccharide antigen A (PSA) and
Zymosan were shown to significantly reduce disease severity via induction of various regulatory
cell populations(30, 31, 43). If TLR2 is both necessary to promote EAE development and yet
TLR2 ligands are able to protect from EAE, then TLR tolerance may be playing a role in these
suppression studies.

During my thesis work presented here, I address the role of TLR2 tolerance in EAE and MS, the
complex properties of L654 that require understanding to study this molecule in biological
assays, and the potential role of L654 as a biomarker for MS disease status and disease activity.
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Figure 1-1. Kinetics of EAE.
In a theoretical graph of EAE disease severity, the more severe disease course has an earlier peak
around day 12, while the less severe disease has a later peak near day 17. If these mice were
assessed for Treg: Teff ratio at day 14 (red arrow), the more severe disease may have a higher
ratio, which can be misleading when studying mechanism.
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Figure 1-2. Proposed pathogenesis of MS.
In the “outside-in” theory of MS disease pathogenesis, peripheral activation of autoreactive T
cells allows them to translocate across the BBB and initiate an inflammatory response resulting
in demyelination and neuronal cell death.
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Figure 1-3. Active EAE.
The active model of EAE is induced by immunizing C57BL/6 mice using an emulsion of CFA
with MOG peptide. PAMPs in the CFA activate DCs which in turn present MOG to naïve T cells
in the lymph nodes. T cells are activated and travel to the CNS where they cross the BBB, are reactived by resident APCs and initiate an immune response that damages the neuronal cells.
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Figure 1-4. T cell adoptive transfer EAE.
The adoptive transfer model of EAE is initiated in naïve SJL/J mice transferring previously
activated T cells from a mouse that received an active immunization to a PLP peptide. Activated
T cells travel to the CNS and cross the BBB where they are re-activated by resident APCs and
initiate an immune response that damages the neuronal cells.
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Figure 1-5. Serum L654 is lower in patients with MS.
A) Serum was obtained from MS patients and healthy controls. Total serum lipids were extracted
and analyzed using MRM-MS to quantify L654 compared to the internal standard, Lipid 660.
MS patients n=17, healthy controls n=12; Wilcoxon rank-sum gives ****p<0.0001. B) Serum
was obtained from UCLA Human Brain and Spinal Fluid Resource Center. MS patients n=13 ,
Alzheimer’s disease patients n=15; Wilcoxon rank-sum gives *p<0.041.
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Methods
Mice
SJL/J and C57BL/6 mice were obtained from Jackson Laboratories. Tlr2-/- (TLR2 KO) mice,
bred onto a C57BL/6 background, were a generous gift of Dr. S. Akira (Osaka University,
Japan). All mice were maintained and bred in accordance with University of Connecticut Center
for Laboratory Animal Care regulations.

Reagents
MOG35–55 and PLP139-151 were synthesized by GenScript (Piscataway, NJ). Complete Freund's
adjuvant (CFA) or Mycobacterium Tuberculosis H37 Ra from BD Difco (Franklin Lakes, NJ)
was suspended in IFA was obtained from Sigma-Aldrich (St. Louis MO.) Purified Pam2CSK4
(Pam2Cys), purified Lipoteichoic Acid (LTA), ODN 1668 and R848 were obtained from
Invivogen (San Diego, CA). S. Minnesota R595 -Monophosphoryl Lipid A was obtained from
Invivogen (San Diego, CA). IgM Monoclonal Antibody to Lipid A (free) – Low Endotoxin was
obtained from Acris Antibodies (AM26275LE-N, San Diego, CA). IgG Monoclonal antibody to
synthetic Lipid A was obtained from Santa Cruz Biotechnology, Inc. (sc-57902, Santa Cruz,
CA). Goat Anti-Mouse IgG (Fc specific)-Peroxidase antibody was obtained from Sigma-Aldrich
(A2554, St. Louis, MO). Goat Anti-Mouse IgM (µ-chain specific) Peroxidase Conjugate was
obtained from Sigma-Aldrich (A8786, St. Louis, MO). PierceTM Protein-Free (PBS) Blocking
Buffer was obtained from Thermoscientific (Waltham, MA). ABTS® ELISA HRP Substrate and
ABTS® Peroxidase Stop Solution were obtained from Kirkegaard & Perry (Gaithersburg, MD).
EZ-LinkTM Amine-PEG11-Biotin was obtained from Thermoscientific (Waltham, MA). DBCOSulfo—NHS ester to link to 654 and Azido-PEG4-NHS ester to link to KLH was obtained from
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Click Chemistry Tools (San Diego, CA). BBL biosate peptone, trypticase peptone, yeast extract
and brain heart infusion, and HPLC solvents were obtained from Fisher Scientific (Waltham,
MA). Acetyl chloride, R (-) α-methoxy-α-trifluoromethylphenylacetyl chloride, D and L serine,
snake venom (Ophiophagus hannah, King Cobra), porcine pancreatic phospholipase A2 (PP
PLA2, >600 units/mg protein), honey bee venom (HBV) PLA2 (Apis mellifera, 600-2400
units/mg protein), PLA1 from Thermomyces lanuginosus, PLC (Clostridium perfringens, 10-50
units/mg protein), PLD (Arachis hypogaea, 300-700 units/mg protein), lipoprotein lipase
(Pseudomonas sp., >50,000 units/mg protein), esterase from porcine liver (>15 units/mg protein)
and diisopropylethylamine were obtained from Sigma Aldrich (St. Louis, MO). Collagenase P
(Clostridium histolyticum 1.8 U/mg protein) was obtained from Roche (Indianapolis, IN).
Lipopolysaccharide A (LPS) (Salmonella typhimurium and trypsin (0.25%) in EDTA (1X) were
obtained from Gibco (Waltham, MA). Pentafluorobenzyl bromide and N,Obis(trimethylsilyl)triflouroacetamide (BSTFA) were obtained from Thermo Scientific (Waltham,
MA). Synthetic CH3-3-OH isoC17:0, isobranched (iso) C15:0 and anteiso C15:0 were obtained from
Matreya LLC (State College, PA).

In Vitro Tolerance Assays
Bone-marrow derived macrophages (BMDMs) were isolated from C57BL/6 mice by flushing
marrow from femur and tibia of mice and culturing the cells obtained in 10% FBS and 10%
L929 supernatant in DMEM. Cells were cultured for 24 hours and non-adherent cells were replated for another 6 days of culture. To obtain L929 supernatant, L929 cells from ATCC
(Manassas, VA) were cultured in 10% RPMI for one week after confluence was reached. Assay
media consisted of the BMDM differentiation media without L929 supernatant. BMDMs were
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pre-treated with 500 pg/ml, 1 ng/ml or 5 ng/ml of Pam2Cys, 1 µg/ml, 5 µg/ml, or 7 µg/ml of
L654 or vehicle control (VC) for 24 hours. Cells were washed and a secondary TLR2 stimulus
was provided by the addition of 5 ng/ml of Pam2Cys. Cells were then cultured for another 24
hours and supernatant was collected. TNFα in the supernatant was measured by the Ready-SETGo!® ELISA kit from Affymetrix Incorporated (Santa Clara, CA).

In Vivo Tolerance Assays
SJL/J mice were intravenously administered 0.35 µg of Pam2Cys in PBS or PBS alone (VC)
daily for 5 days. 300 µg of LTA was intravenously administered to mice after 1, 3, or 5 days of
Pam2Cys/VC treatment, mice were bled 2 hours later and serum TNFα assayed by ELISA. In
cross-tolerance studies, SJL/J mice were treated with Pam2Cys or VC as above and 40 µg of
ODN 1668 was intravenously administered or 60-80 µg of R848 (InvivoGen, San Diego, CA)
was intraperitoneally administered 1 day after the last Pam2Cys/VC administration. Mice were
bled 1.5 hours later and serum TNFα assayed by ELISA.

T cell adoptive Transfer EAE
The PLP139-151-specific model of adoptively transferred EAE in SJL/J mice was used in all EAE
studies (44). Briefly, draining LNCs from mice immunized 9 days prior with PLP139-151 in
complete Freund’s adjuvant were re-stimulated in vitro with PLP139-151. After 4 days the cultured
cells (29 x 106 cells/mouse) were transferred intraperitoneally to naive female SJL/J mice. No
pertussis toxin is used in this protocol. Clinical grading of EAE as previously described (45) was
performed daily on all mice for 60 days.
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Flow Cytometric Analysis
Spleens are harvested and a single cell suspension is prepared, restimulated for 4 hours with 200
ng/ml of phorbol 12-myristate 13-acetate (PMA), 1 µg/ml of Ionomycin and 5 µg/ml of Brefeldin
A (BFA) from Sigma Aldrich (St. Louis, MO) and stained. Mononuclear cells from the spinal
cord are obtained by first perfusing mice through the left cardiac ventricle with cold PBS and
dissecting the spinal cords. CNS tissue was cut into pieces and digested with 2.5 mg/ml
collagenase D obtained from Roche Diagnostics (Indianapolis, IN) and 1 ml/ml DNaseI obtained
from Sigma Aldrich (St. Louis, MO) at 37 °C for 45 min. Mononuclear cells were isolated by
passing the tissue through a 70 µm cell strainer, followed by a 70% to 37% percoll gradient
centrifugation. Mononuclear cells were removed from the interphase, washed and resuspended in
culture medium. Cells were restimulated as above, and stained(1). Cells were blocked with antimouse CD16/32 from Biolegend (101302; San Diego, CA) and stained with anti-mouse CD4BV510, CD8-BV650, CD11b-FITC, CD45.1-Pacific BlueTM, CD11c-Alexa Fluor® 700, F4/80PE/Cy7, and/or CD19-BV570 from Biolegend (100559, 100742, 101206, 110722, 117319,
123113 115535; San Diego, CA), CD39-PerCP-EF710 and/or MHCII-AF700 from Affymetrix
Incorporation (46-0391, 56-5321-82; Santa Clara, CA), CD80-PE from BD Biosciences
(553769; San Jose, CA), L/D Near IR from Molecular Probes (L34975; Eugene, OR), and/or
CD62L-PE from Tonbo Biosciences (50-0621; San Diego, CA). Cells were permeabilized and
fixed using the Fixation/Permeabilization Solution Kit and suggested protocol from BD
Biosciences (554714; San Jose, CA) and stained with anti-mouse IFNγ-violetFluorTM450 from
Tonbo Biosciences (75-7311; San Diego, CA), IL-17A-PE-Cy7 from Biolegend (506921; San
Diego, CA), IL-10-APC, GMCSF-FITC and/or TNFa-PercP-eFluor®710 from Affymetrix
Incorporation ((17-7101-81, 11-7331, 46-7321-80; Santa Clara, CA). For FoxP3 staining the
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FoxP3/Transcription Factor Staining Buffer Set Kit and suggested protocol were obtained from
Affymetrix Incorporated (00-5523-00; Santa Clara, CA). Cells are analyzed by flow cytometry.

Human serum, plasma, PBMC and monocyte derivation
After consent is obtained, 20 ml of blood is drawn from patients who had not eaten for at least
two hours. Serum is derived as previously described and frozen at -800 C(35). Plasma was
derived by collecting blood in pre-coated ethylenediaminetetraacetic acid (EDTA)-lined tubes
and then spinning them at 1750 relative centrifugal force (RCF) for 15 minutes at room
temperature with the break off. Plasma was removed to a new tube and frozen at -800 C.
Peripheral blood mononuclear cells (PBMCs) were derived by collecting blood in pre-coated
EDTA-lined tubes. Blood was diluted 1:2 in 2% fetal bovine serum in PBS. A 50 ml SepMateTM50 tube and 15 ml of LymphoprepTM ,both obtained from Stem Cell Technologies (Vancouver,
Canada), was added to the bottom. The diluted blood was added on top and the tube was spun
down at 1200 RCF for 10 minutes at room temperature with the break on. Supernatant was
poured off into a new 50 ml tube and spun down for 5 minutes at 2000 RCF at 4 degrees. Cells
were washed twice before use in biological assays. Monocytes were directly isolated after blood
was collected in pre-coated EDTA-lined tubes. Using the EasySepTM Direct Human Monocyte
Isolation Kit from Stem Cell Technologies (Vancouver, Canada), the suggested protocol was
followed.

PBMC and monocyte stimulation and TLR2 expression analysis
After PBMC or monocyte isolation, cells were blocked with human FcR Blocking Reagent from
Miltenyi Biotec (130-059-901, Auburn, CA) and stained with anti-human CD14-APC from
Tonbo Biotechnologies Coropration (20-0149, San Diego, CA) and TLR2-PE from Affymetrix
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Incorporated (12-9922-41, Santa Clara, CA) or isotypes and analyzed by flow cytometry.
PBMCs were plated at 1x106/ml and monocytes were plated at 1x105/ml and stimulated with 2
µg/ml or 10 µg/ml of Mitogenic Pentapeptide Palmitoyl-Cys((RS)-2,3-di(palmitoyloxy)-propyl)Ser-Ser-Asn-Ala-OH (MMP) from Bachem Americas Inc (H-9460.0005) for 4 hours. Human
TNFα was measured in the supernatants using the Ready-SET-Go!® ELISA kit from Affymetrix
Incorporated (Santa Carla, CA).

Bacterial growth
Bacteria were grown in broth culture as previously described. P. gingivalis from ATCC #33277,
Manassas, CA) was inoculated into basal (peptone, trypticase and yeast extract) medium
supplemented with hemin and menadione (Sigma, St. Louis, MO) and brain heart infusion (46).
Culture purity was verified by lack of growth in aerobic culture and formation of black colonies
when inoculated on blood agar plates and grown under anaerobic conditions. The suspension
cultures were incubated in an anaerobic chamber flushed with N2 (80%), CO2 (10%) and H2
(10%) at 37°C for four days and the bacteria were harvested by centrifugation (3000 g for 20
min).

Purification of L654
Lipids were extracted from lyophilized bacterial pellets of P. gingivalis. Generally 2 to 4 g of
bacterial pellet was extracted for each semipreparative fractionation. The bacterial samples were
weighed and dissolved in chloroform:methanol:water (1.33:2.67, 1, v/v/v, 2g of bacterial pellet
in a total of 16 ml of solvent). The mixture was vortexed at 15 minute intervals and after at least
2 hours, the mixture was supplemented with 6 ml of chloroform and 6 ml of 2N KCl + 0.5N
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K2HPO4. The mixture was vortexed and centrifuged at 20°C for 45 minutes. The lower organic
phase was removed and dried under nitrogen. The dried extract was reconstituted in HPLC
solvent (hexane:isopropanol:water, 6:8:0.75, v/v/v, 18 ml) and vortexed. The sample was
centrifuged at 2500 x g for 10 minutes and the supernatant removed for HPLC analysis.
Semipreparative HPLC fractionation was accomplished using a Shimadzu HPLC system with
normal phase separation (Ascentis®Si, 25 cm x 10 mm, 5 um, Supelco Analytical).
Fractionations used a solvent flow of 1.8 ml/min and 1 min fractions were collected. The effluent
was monitored at 205 nm. Replicate fractionations were pooled and dried under nitrogen. Lipid
654 fractions were further purified by elution over the same HPLC column at 1.8 ml/min but
using HPLC solvent supplemented with 0.1% acetic acid. Purity of Lipid 654 was verified by
electrospray-mass spectrometry (ESI-MS or MS/MS) as described below. Following hydrolysis
of Lipid 654 with PP PLA2 for 4 days, fractionation of Lipid 654 from Lipid 430 was
accomplished using the same acidic fractionation as previously described. Lipid 430 mass
spectral characteristics were verified using ESI-MS and ESI-quadrupole time of flight (QTOF)MS/MS (AB Sciex QStar instrument) The dried samples were reconstituted in HPLC solvent for
mass spectrometric analysis as described below. Based on the MS profiles, selected fractions
were weighed and aliquoted for biological testing as described below.

Identification of L654
Lipid samples in HPLC fractions from either semi-preparative neutral or acidic fractionations,
were dissolved in the neutral HPLC solvent described above and were injected over a normal
phase column (Ascentis®Si, 3 cm x 2.1 mm, 5 mm, Supelco Analytical) interfaced with an
API4000 4000 Qtrap instrument from Sciex. Neutral HPLC solvent was delivered under
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isocratic conditions with a Shimadzu LC-10ADvp pump at a flow rate of 100-120 µl/min. Total
ion chromatograms were acquired using negative ion mode and a mass range of 100 to 1800
amu, and MS/MS acquisitions used parameters optimized for specific lipid products. Collision
energies for negative ion products were typically between -30 and -55 volts depending on the
precursor ion under investigation. Negative ion ESI was carried out at -4,500 V, with a
declustering potential of -90 V, focusing potential of -350 V, and entrance potential of -10 V.
Multiple reaction monitoring (MRM) negative ion transitions for Lipid 654 were 653.5/131.1,
653.5/306.2, 653.5/349.3 and 653.5/381.4 m/z and transitions for Lipid 430 were 430.2/140.9,
430.3/173.1 and 430.3/382.3 m/z. Lipid 430/Lipid 654 ratios were calculated using the area of
extracted ion chromatograms (XIC) only for the 430.3/382.3 and 653.5/381.4 m/z transitions.

In Vitro assays for L654 testing
The HEK-BlueTM hTLR2 cell line was obtained from Invivogen (San Diego, CA). Cells were
cultured in suggested media at 2.4x105 cells/ml for 24 hours. Cells were then stimulated with
LTA or L654 at various concentrations as described in each figure for 24 hours. Interleukin-8
(IL-8) was measured in the supernatant using the Human IL-8 OptEIA ELISA Set from Becton,
Dickinson & Co (Franklin Lakes, NJ).

General serum lipid extraction procedure
If an ideal internal standard was available we aliquoted 0.1-1 µg into clean glass tubes and let it
dry down overnight. The next day, 500 µl of serum was aliquoted into tubes containing internal
standard. Then 2 ml 1:2 (v:v) chloroform:methanol was added to each tube and vortexed. Tubes
incubated at room temperature for 30 minutes. At this point, 0.75 ml of chloroform and 0.75 ml
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of 2N KCl + 0.5N K2HPO4 was added to each tube. Tubes were vortexed and spun down at 2000
rpm for 10-20 minutes in a swinging bucket centrifuge. The lower, organic, phase was removed
and placed into a new glass vial to dry overnight. When ready to use, samples were resuspended
in 200 µl of Solvent A (6:8:0.75 [v:v:v] hexanes: isopropanol: water) and analyzed by MRMMS.

Acidic serum lipid extraction procedure
300 µl of serum was aliquoted. 1 ml of deionized water, 100 µl of glacial acetic acid, and 2 ml of
chloroform were added. Serum was spun at 2000 RCF for 10 minutes. The lower, organic, phase
was removed and placed into a new glass vial to dry overnight. When ready to use, samples were
resuspended in 200 µl of Solvent A (6:8:0.75 [v:v:v] hexanes: isopropanol: water) and analyzed
by MRM-MS.

Statistical Analyses
Data are expressed as the means ± standard errors. Statistical testing included an analysis of
variance (ANOVA) for comparisons between more than two normally distributed groups, a
Wilcoxon Rank Sum for comparisons between more than two non-parametric groups,
Student t test for comparisons between more than two normally distributed groups or MannWhitney U test for non-parametric analysis between two groups.
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Chapter 2 TLR tolerance as a treatment of CNS autoimmunity
Abstract
The role of Toll-like receptor (TLR) signaling in Multiple Sclerosis (MS) and experimental
autoimmune encephalomyelitis (EAE) is unclear. We recently reported that a microbiomederived TLR2 ligand, Lipid 654 (L654), is present in healthy human serum but significantly
decreased in the serum of MS patients. This suggested that microbiome products gaining access
to the systemic circulation may normally play an immune-regulatory role by tonically
maintaining a state of relative TLR tolerance. Therefore, a loss of microbiome-mediated TLR
tolerance may play a role in the pathogenesis of MS.

As a proof of concept we asked whether administering low-level TLR2 ligands in adoptive
transfer EAE induces TLR2 tolerance and attenuates disease. We administered low-level
Pam2Cys or L654 to mice receiving encephalitogenic cells and in doing so induced both TLR2
tolerance and attenuation of EAE. Disease attenuation was accompanied by a decrease in central
nervous system (CNS) macrophage activation, CD11c+F4/80+ cells and Th17 T cells and an
increase in splenic type 1 regulatory T cells. Kinetic studies revealed a critical period in which
TLR2 inactivation was most efficient in attenuating EAE. Importantly, monocytes from patients
with progressive or active MS were hyper-responsive to stimulus with a TLR2 ligand compared
to both relapsing-remitting MS patients and control patients. These results suggest that
enhancing the TLR tolerance normally mediated by the microbiome may offer a new approach to
treating CNS autoimmune diseases such as MS.
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Introduction
Multiple sclerosis (MS) is a progressive demyelinating disease of the central nervous system
(CNS) that affects one in one thousand people in the United States. There is both a genetic and
environmental component to the disease etiology, though these contributions have yet to be
understood. Treatments for MS are currently based on a limited understanding of the disease
pathogenesis, are broadly immunosuppressive and largely target T and B cells.

We have previously reported that a microbiome-derived Toll-like receptor 2 (TLR2) agonist,
Lipid 654 (L654), is present in the circulation of healthy individuals. Importantly, L654 is
recovered in significantly lower levels in the serum of patients with MS (47). While pathogen
associated molecular patterns (PAMPS) such as L654 are normally thought of as proinflammatory, we asked whether a decrease in TLR2 ligands could have relevance to the disease
pathogenesis of MS.

TLR2 expression has been reported to be upregulated on oligodendrocytes and on peripheral
blood mononuclear cells of MS patients (36, 37). In the mouse model of MS, experimental
autoimmune encephalomyelitis (EAE), TLR2 expression has been reported to be upregulated in
the spinal cord (38). Despite this increase in expression, the role of TLR2 has remained unclear.
The disease severity of TLR2-deficient mice compared to wildtype (WT) mice in various EAE
models is controversial. TLR2-deficient mice have been shown to variably develop comparable
disease severity, attenuated disease severity, or no disease at all in both active disease and
adoptive transfer models of EAE (38-42). As no adjuvant is utilized in most adoptive transfer
models of EAE, this potential TLR2-dependence suggests that either endogenous danger
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associated molecular patterns (DAMPS) or microbiome-derived TLR2 ligands are involved in
disease pathogenesis. Moreover, TLR2-deficient mice are reported to have a decreased number
of systemic T helper 17 (Th17) T cells lending further support for a potential role of TLR2 in
promoting EAE (41).

In contrast to the potential requirement for TLR2 in the EAE disease process, other studies have
reported that administering relatively large amounts of TLR2 ligands can attenuate EAE through
induction of various regulatory T cell populations (30, 31, 43). Thus, while the literature appears
contradictory in suggesting both a requirement for and inhibitory capacity of TLR2 signaling in
EAE, the concept of TLR tolerance can potentially resolve this dilemma. It has been well
documented that repeated ligation through TLRs results in subsequent signal dampening and a
state of “TLR tolerance” which prevents successive ligations from signaling at normal magnitude
(48). If TLR2 signaling is truly disease promoting in EAE, then a dampening of this signaling
pathway through repeated ligation and tolerance development would lead to disease attenuation.

The role and underlying mechanisms of the microbiome in regulating systemic immunity and
autoimmunity remain unclear. Our recent findings of lower serum L654 levels in patients with
MS (47) suggested that microbiome products gaining access to the systemic circulation might
normally play an immune-regulatory role by maintaining a state of relative TLR tolerance. In
this way, tonic interaction of TLRs with low-level microbiome-derived ligands can establish the
threshold and magnitude of systemic TLR signaling. Therefore, a loss of microbiome-mediated
TLR tolerance may play a role in the pathogenesis of MS.
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In proof of concept studies we now show that mimicking the microbiome by administering a
low-level canonical TLR2 ligand or the human serum-accessing microbiome product, L645,
induces TLR tolerance and attenuates adoptively transferred EAE. In doing so, we suggest that
TLR tolerance is a normal mechanism of microbiome-mediated immune-regulation, abnormal in
MS, and a potential new therapeutic approach for patients with MS.

Results
TLR2 tolerance can be induced both in vitro and in vivo using canonical TLR2 ligands or L654
With the goal of developing a TLR2-induced tolerance protocol that could eventually be applied
to EAE, we first confirmed that canonical TLR2 ligands can tolerize mouse bone marrow
derived macrophages (BMDMs). We also tested the ability of L654, a microbiome-derived,
TLR2 ligand that is capable of accessing the human circulation, to tolerize BMDMs (47).
BMDMS were pre-treated with Pam2Cys, L654, or vehicle control (VC) for 24 hours. The
primary TLR2 stimulus was removed, the cells washed, and a secondary TLR2 stimulus
(Pam2Cys) added for an additional 24 hours. The resulting concentration of TNFα in the culture
supernatants was then assayed by ELISA. The level of TNFα was significantly decreased by both
Pam2Cys and L654 pre-treatment compared to pre-treatment with VC (Fig. 1A and 1B).

To determine whether a canonicalTLR2 ligand can have a systemic tolerizing effect in vivo, we
intravenously administered low-dose Pam2Cys or VC once daily for 5 consecutive days to SJL/J
mice. On day 6, lipoteichoic acid (LTA) was administered and mice were bled 2 hours later and
serum TNFα concentration assayed by ELISA. The induction of serum TNFα by LTA was
almost completely inhibited in the mice that were pre-treated with Pam2Cys (Fig. 1C). To
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determine if L654 could also induce in vivo TLR2 tolerance, we used this 5-day protocol pretreating with 5 µg of Lipid 654. Though less efficient than Pam2Cys, pre-treatment with L654
also significantly decreased the levels of LTA-induced serum TNFα (Fig. 1D). To determine the
length of time during which in vivo induced TLR2 tolerance persists, mice were administered
VC or Pam2Cys once daily for 5 consecutive days. On Day 1, 3, or 5 after the last injection of
Pam2Cys, mice were administered LTA and 2 hours later serum was obtained and assayed for
TNFα by ELISA. At both 1 and 3 days following the last injection of Pam2Cys, mice still
demonstrated tolerance to LTA stimulation. By day 5 after Pam2Cys, this tolerance was still
present but no longer reached statistical significance (Fig. 1E).

Induction of TLR2 tolerance attenuates adoptively transferred EAE
Using this in vivo tolerance-induction protocol, we induced systemic tolerance at various time
points during adoptively transferred EAE development. We utilized the well-characterized model
of EAE induced by the adoptive transfer of PLP-activated lymph node cells (PLP-LNCs) into
naive SJL/J mice (44). This model involves no administration of exogenous TLR ligands.
Recipient mice were intravenously administered VC or low-dose Pam2Cys once daily for 5
consecutive days. Injections were given to recipient mice beginning at day -2 before PLP-LNC
cell transfer, between day +4 or +6 (+4/+6) post cell transfer, or beginning at day +8 post cell
transfer. Disease severity was recorded daily for 60 days. Initiating the 5-day TLR2 tolerance
protocol at day -2 or day +8 did not affect the time of disease onset (Fig. 2A and 2C). In contrast,
the day +4/+6 protocol resulted in a significant delay of disease onset that lasted approximately 5
days (p<0.0001; Fig. 2B).
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Interestingly, this approximate 5-day delay in onset and severity of clinical disease noted using
the day +4/+6 tolerance induction protocol was consistent with our documented kinetics of
tolerance persistence (Fig. 1E). Additionally, we confirmed that TLR2 tolerance was induced
during the noted delay in EAE disease. To do so, LTA was administered on day 7 to mice that
had been treated with either VC or Pam2Cys from day 4 through day 6 after PLP-LNC transfer.
As seen in Figure 2d, mice pre-treated with Pam2Cys demonstrated systemic tolerance to LTA
administration. Overall, these results suggest that although exogenous PAMPS are not
administered in this model of EAE, TLR2 tolerance is capable of inhibiting disease onset and
severity when present between day +4 and day +10 after PLP-LNC transfer. We suspect that the
day +4/+6 protocol likely affects the phase of EAE pathogenesis that involves T cell entry and
re-stimulation in the CNS, but future studies in our laboratory will interrogate this question
directly.

Two other effects of the tolerance-inducing protocol were noted. While no delay in disease onset
was observed when the protocol was initiated on day -2, an attenuation in disease severity over
the chronic 60-day course of the disease was consistently noted both with the day -2 initiated
protocol and with the day +4/+6 initiated protocols (Fig. 2A and 2B). The potential causes of this
chronic attenuation are addressed below. The second observed effect of the tolerance-inducing
protocol was a small but consistent enhancement of disease in mice treated with the protocol
beginning at day +8 post PLP-LNC transfer (Fig. 2C). We believe this is likely a result of the
adoptively transferred T cells being re-activated in vivo prior to the establishment of TLR2
tolerance and will also be further investigated in future studies. Overall, these results suggest for
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the first time that TLR2 tolerance can attenuate adoptive transfer EAE and that this involves both
a delay in disease onset and attenuation in chronic disease severity.

The human microbiome-derived product, L654, attenuates EAE
We have previously reported that L654 is a microbiome-derived TLR2 ligand detectable in all
serum samples obtained from healthy individuals but significantly lower in the serum of patients
with MS (47). We next asked if L654 might normally be contributing to immune homeostasis
and prevention of CNS autoimmune disease through TLR2 tolerance induction. To test this
concept, we asked if L654 was capable of attenuating EAE if administered in our 5-day
tolerance-inducing protocol during the day+4/+6 window. Recipient mice were administered VC
or L654 using the day +4 initiated protocol. As with Pam2Cys administration, L654 was able to
both delay disease onset and attenuate the severity of the chronic phase of the disease (p<0.0001;
Figure 3). We found that L654 usually resulted in a shorter delay in disease onset compared to
that seen using Pam2Cys and this is consistent with the relative strength of TLR2 tolerance
induced by these ligands (Fig. 1D). L654 did however result in attenuation of chronic disease
severity that was comparable to that seen using Pam2Cys (Fig. 3). This suggests that L654, as a
microbiome-derived molecule that accesses the human circulation, may aid in regulating TLR2
responses through low-level, tonic signaling and tolerance induction. In this paradigm, the
decreased recovery of L654 in MS serum samples may indicate a deficiency in this tonic TLR
regulatory function in MS.

Induction of TLR2 tolerance cross-tolerizes to the other TLRs implicated in EAE pathogenesis
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It has been documented that inducing tolerance to a specific TLR can also induce cross-tolerance
to other TLRs (49, 50). Therefore, we asked if our 5-day TLR2 tolerance protocol induces crosstolerance to signaling through other TLR molecules. Because Toll-like receptor 9 (TLR9) and
Toll-like receptor 7 (TLR7) have been implicated in EAE disease pathogenesis (38, 40, 51), we
specifically asked if our TLR2 tolerance induction protocol cross-tolerizes mice to TLR7 and
TLR9. We administered VC or low-dose Pam2Cys to naive SJL mice for 5 consecutive days and
on day 6 we administered either ODN 1668, a TLR9 ligand, or R848, a TLR7/8 ligand. Serum
TNFα induced by the TLR9 or TLR7/8 ligand was assessed by ELISA. Mice pre-treated with our
5-day Pam2Cys protocol demonstrated a decreased serum TNFα response to both ODN 1668 and
R848 (Fig. 4). Therefore, our TLR2 tolerance protocol induces cross-tolerance to the other TLRs
implicated in EAE. These results indicate that we cannot implicate tolerance only through TLR2
as underlying the disease attenuation we have noted. Importantly however, these results suggest
that the induction of TLR tolerance may be a highly efficient microbiome-mediated mechanism
for simultaneously regulating responses through many TLRs. Moreover, our results suggest that
inducing tolerance with even a single TLR2 ligand may be an effective approach for attenuating
disease in MS.

CNS macrophage CD80-expression, F4/80+CD11c+ cells producing TNFα and Th17 T helper
cells are decreased while splenic Tr1 regulatory T cells are increased after induction of TLR2
tolerance
To determine the disease-relevant immune effector and regulatory alterations associated with
induction of TLR2 tolerance in EAE, recipient mice were intravenously administered VC or
Pam2Cys for 5 days on day +4 through +8 post cell transfer. Mice were then sacrificed on day
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+12 and spleen and spinal cord mononuclear cells were harvested and prepared for flow
cytometric analysis using standardized approaches. At day +12, the tolerized mice showed either
no clinical signs or had clinical signs which were significantly less than those seen in the VCtreated cohort.

We found that the tolerized mice demonstrated, on average, fewer mononuclear cells infiltrating
the spinal cord (data not shown). These results were at least partially a result of the greater
frequency of mice in this cohort that had too few cells in the spinal cord to study. However, in
tolerized mice in which cells could be recovered and characterized from the spinal cord, we
noted three significant differences in the CNS populations compared to the control cohort of
mice.

First, the tolerized mice demonstrated a significant decrease in the expression of the
costimulatory molecule CD80 on CNS F4/80+ macrophages (p=0.0248;Fig. 5A). A decrease in
CD80 expression on F4/80+ macrophages is indicative of diminished activation of these
macrophages and is consistent with what has been shown in studies of TLR tolerance (52, 53). A
state of diminished activation of F4/80+ macrophages is associated with decreased antigenpresentation ability and thus is likely an important mechanism underlying the decreased spinal
cord cellular inflammation and decreased disease manifestations seen in the tolerized mice.
Specifically, we hypothesize that the delay in disease onset we have noted is a result of a
diminished activation state of CNS macrophages that are involved in re-activating pathogenic T
cells that have trafficked into the CNS during the day +4 through day +10 interval.
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Second, tolerized mice demonstrated a significant decrease in CNS F4/80+CD11c+ cells
(****p<0.0001;Fig. 5B). The role of CNS F4/80+CD11c+ cells in EAE has not been extensively
reported, but in other contexts cells with this phenotype have been reported to serve either an
inflammatory or regulatory function(54, 55). Although we found a significant decrease in
percentage of these cells in the CNS of tolerized mice, the cells exhibited a pro-inflammatory
phenotype in both control and tolerized cohorts as evidenced by their production of TNFa (data
not shown). The function and significance of these cells in EAE will be a topic of future study in
our laboratory.

Third, while there was no difference in absolute number of CNS CD4+ T cells
in tolerized mice (in which CNS cells were sufficient to characterize) compared to VC-treated
mice (data not shown), the tolerized mice demonstrated a significant decrease in the proportion
of CNS CD4+ T cells that were Th17 cells (Fig. 5C). Interestingly, this decrease was not
observed in CNS Th1 cells (Fig. 5D), in granulocyte-macrophage colony-stimulating factor
(GM-CSF) producing T cells or in T cells that produced both IL-17 and IFNγ (data not shown).
CD4+ Th17 T cells are believed to be the most pathogenic subset of CD4+ T cells in EAE, so this
finding is consistent with the tolerized mice having significantly less disease than the control
mice. Reynolds et al. have previously demonstrated that optimal Th17 T cell generation is
dependent on TLR2 expression (41). Thus, it is possible that the decrease in CNS Th17 T cells
noted in the tolerized mice is a direct result of TLR2 tolerance induced in the encephalitogenic T
cells in the transferred PLP-LNC population. However, these T cells have been activated initially
in vivo and then again for 4 days in vitro. Therefore, it is likely that most of the differentiation of
the PLP-specific CD4+ T cells into Th1 or Th17 subsets occurs before they are exposed to the in
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vivo tolerance inducing protocol initiated 4 days after transfer. Nevertheless, it is conceivable
that either some of the PLP-specific T cells undergo initial differentiation after adoptive transfer
and/or that functionally inhibiting TLR2 responsiveness in the adoptively transferred T cells has
effects on their migration or survival in the recipient mice. This will be a topic of future studies
in our laboratory.

Finally, we also noted a third difference between tolerized and control mice when comparing
splenic regulatory T cell (Treg) populations. Previous reports in which TLR2 ligands were
administered or TLR2 was genetically deleted in mice with EAE showed an increase in either
CD39-expressing or CD62L-expressing Tregs. (31, 40). It should be noted that in these studies
significantly larger concentrations of TLR2 ligands were administered (100 µg) than were used
in our tolerance studies (0.35 µg Pam2Cys and 5 µg L654). Nonetheless, we asked whether
regulatory T cells may also be contributing to the attenuation of EAE seen in TLR2 tolerized
mice. We found no significant increase in the percentages of FoxP3+CD4+ T cells,
CD39+FoxP3+CD4+ T cells, or CD39+CD4+ T cells in the spleens or spinal cords of tolerized
versus control mice (Fig. 5E-G). Similarly, no significant increase was seen in the
CD62L+FoxP3+CD4+ populations in the spleen or CNS of tolerized mice (data not shown).
However, we did observe a significant increase in the percentage of CD4+ FoxP3- IFNγ+ IL-10+
type 1 regulatory T cells (Tr1) in the spleens of the tolerized mice (p=0.0056; Fig. 5H). This
difference was not seen in the spinal cords of these mice. Thus, our tolerance protocol did not
recapitulate an increase in the specific Treg populations reported previously, but rather resulted
in an increase in the population of splenic Tr1 Tregs. Given that Th17 T cells have been shown
to be most efficiently regulated by IL-10 producing T cells such as Tr1Tregs (56), it is possible
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that this increase in Tr1 Tregs is at least partially responsible for both the decreased percentage
of CNS Th17 T cells and the attenuation of chronic disease severity observed in tolerized mice.

Monocytes from progressive MS patients are hyper-responsive to TLR2 stimuli despite similar
expression of TLR2
Peripheral blood mononuclear cells or monocytes were isolated from blood obtained from
patients with multiple sclerosis or healthy controls. Patients were categorized as progressive and
having currently active disease or as relapsing remitting patients and having currently inactive
disease. Cells were stimulated with vehicle, LPS or MMP at varying doses and TNFα was
measured in the supernatant. There was no TNFα produced by cells treated with only vehicle
control (data not shown). MS patients with active disease had significantly increased production
of TNFα compared to healthy controls or MS patients with inactive disease when stimulated with
the TLR2 ligand, MMP (Figure 2-6a). Though a potential trend was seen when stimulated with
the TLR4 ligand, LPS, there was no significant difference between any groups (Figure 2-6B).
The increased production of TNFα after TLR2 stimulation is not due to increased TLR2
expression as there was no difference in expression found (Figure 2-6C). This can be visualized
when results are expressed as TNFα production per million %TLR2+CD14+ cells (Figure 2-6C).

Discussion
We have previously reported that L654, a microbiome-derived TLR2 ligand, can be identified in
the serum of all healthy individuals but is significantly lower in the serum of MS patients (47).
These findings led us to ask why a TLR ligand, normally thought of as pro-inflammatory, would
be lower in the setting of an autoimmune disease such as MS. The concept of TLR tolerance
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offered one possible mechanism for the association of a lower level of TLR ligands with an autoinflammatory disease.

We postulated that microbiome-derived products, like L654, which gain access to the systemic
circulation may normally regulate the systemic immune system by inducing a state of relative
TLR tolerance. As such, when circulating levels of microbiome-derived products are low, the
normal induction of TLR tolerance may be inadequate resulting in a lower threshold of initiation
and higher magnitude of responses in innate immune cells. This may then contribute to autoinflammatory diseases such as MS. Consistent with this postulate, the relevance of TLR
tolerance as a mechanism of immune-regulation in human disease was recently demonstrated for
allergy, hay fever, and asthma (57). In addition, this postulate is similar to a mechanism
proposed for NOD2-induced tolerance that normally occurs in the GI tract but is defective in a
subset of patients with Crohn’s disease (58).

While T cells and the adaptive immune system have been the major research focus in EAE and
MS, the role of TLRs has not been extensively studied in these diseases. In the few studies of
EAE that utilize TLR2-deficient mice, a role for TLR2 has been demonstrated, albeit
inconsistently, in both actively induced and passive models of EAE (38-42). In actively induced
EAE, adjuvants containing numerous TLR ligands are required. However, in most T cell
adoptive transfer models, no exogenous TLR ligands are administered. Therefore, it is surprising
that a TLR2-dependence has been demonstrated in these adoptive transfer models (40).
Additionally, TLR2-deficient mice have been shown to have a decreased number of systemic
Th17 cells, a T cell subset known to contribute to EAE disease pathogenesis (41). Overall, these
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studies suggest that either endogenous or microbiome-derived TLR ligands are playing an as yet
unidentified role in the pathogenesis of adoptive transfer EAE and, by extension, in MS.

In contrast to the disease-promoting effect of TLR2 in EAE, other studies have shown that TLR2
ligands can inhibit EAE. The TLR2 ligands, polysaccharide A and Zymosan, when administered
to mice during EAE (in the range of approximately 100 µg per day) significantly reduced disease
severity via induction of various subsets of Tregs (30, 31, 43, 59-64). In the present studies, we
postulated that TLR tolerance could explain the TLR2 paradox in EAE as well as offer a
potential mechanism for microbiome-mediated immune-regulation.

TLR tolerance in autoimmunity, while investigated in murine models of type 1 diabetes (53), has
rarely been studied in the context of either TLR2 or EAE (51, 53). In the only study examining
this concept in EAE, tolerance induction using TLR7 ligands was shown to attenuate active
immunization (i.e., not adaptive transfer) EAE models (51). However, in that study it was also
demonstrated that the TLR7 ligands cross-tolerized to TLR2. In the present studies our goal was
to test, as proof-of-concept, TLR tolerance as a mechanism underlying microbiome-mediated
immune-regulation. Specifically, we focused on testing this concept in a model for MS and
utilizing adoptive transfer EAE in which no exogenous TLR ligands are required. Our goal was
also to test this mode of microbiome-mediated immune-regulation using a very low dose of both
a canonical TLR2 ligand (Pam2Cys) and a documented microbiome-derived TLR2 ligand, L654.

Our results now demonstrate that: 1) both low-dose Pam2Cys and L654 can induce in vitro and
in vivo TLR2 tolerance; 2) when used in a critical day +4 through day +10 kinetic window after
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encephalitogenic T cell transfer, both Pam2Cys and L654 can attenuate EAE; 3) this attenuation
of EAE is associated with in vivo TLR2 tolerance; 4) mechanistically, induced TLR2 tolerance
and attenuated EAE is associated with a significant decrease in both CNS-infiltrating Th17 T
cells, F4/80+CD11c+ cells and CD80-expression on CNS macrophages as well as a significant
increase in splenic Tr1 Tregs; 5) inducing TLR2 tolerance cross-tolerizes to other relevant TLRs
which likely significantly enhances the efficiency of this mode of immune-regulation both via
the microbiome and as a potential new therapeutic approach for MS.

Importantly, we also found TLR2 hyper-responsiveness in monocytes from patients with active
or progressive MS disease compared to those from patients with inactive disease or control
patients. This suggests a potential role for TLR2 hyper-responsiveness in the disease
pathogenesis of progressive MS and during acute relapses of relapsing-remitting MS and
therefore also suggests that TLR tolerance induction may be utilized as an effective treatment for
progressive MS. We have yet to understand the differences in disease pathogenesis between
progressive and relapsing MS, and current treatments have not yet been proven to be efficacious
in treating progressive MS. It will be important to determine if monocytes from patients with
progressive MS are able to be tolerized or if there is an inherent defect in tolerization, both of
which would contribute to our understanding of progressive MS and the potential avenues for
new treatments.

In sum, we now demonstrate that inducing TLR2 tolerance attenuates adoptive transfer EAE.
Moreover, we demonstrate that a microbiome-derived molecule recovered in the serum of all
healthy individuals but found in significantly lower levels in the serum of patients with MS can
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function both to tolerize mice to TLR2 and to attenuate EAE. Our results suggest that mimicking
the normal microbiome by using TLR2 tolerance induction may be a successful approach for
treating MS by raising the threshold and decreasing the magnitude of innate immune responses.
These studies should now provide impetus for further investigation of the relevance of TLR
tolerance induction both as a mechanism underlying microbiome regulation of systemic immune
responses and as a potential new therapeutic approach for CNS autoimmunity.
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Figure 2-1. TLR2 tolerance can be induced both in vitro and in vivo using canonical TLR2
ligands or L654.
A) C57BL/6 BMDMs were treated with 500 pg/ml, 1 ng/ml or 5 ng/ml of Pam2Cys or a VC for
24 hours. Cells were then cultured with a secondary stimulus of 5 ng/ml of Pam2Cys for 24
hours and supernatant TNFα analyzed by ELISA; 1 independent experiment, n=4; **** =
p<0.0001 by ANOVA. B) BMDMs were treated with 1 µg/ml, 5 µg/ml, or 7 µg/ml of L654 or
VC for 24 hours. Cells were then cultured with a secondary stimulus of 5 ng/ml of Pam2Cys for
24 hours and supernatant TNFα analyzed by ELISA; 1 independent experiment, n=6; **** =
p<0.0001 by ANOVA. C) SJL/J mice were intravenously administered VC or 0.35-0.40 µg of
Pam2Cys once daily for 5 days. On day 6 all mice were intravenously administered 300 µg of
LTA, bled 2 hours later, and serum TNFα analyzed by ELISA; 2 independent experiments, n=56; **** = p<0.0001 by Student’s t test. D) SJL/J mice were intravenously administered VC, 5 µg
of L654, or 0.35 µg of Pam2Cys once daily for 5 days. On day 6 all mice were intravenously
administered 300 µg of LTA, bled 2 hours later, and serum TNFα analyzed by ELISA; 1
independent experiment, n=3 mice/group and n=5-6 ELISA wells per group; VC compared to 5
µg of L654 or 0.35 µg Pam2Cys ** = p=0.0042 and **** = p<0.0001, respectively by ANOVA.
E) SJL/J mice were intravenously administered VC or 0.35 µg of Pam2Cys once daily for 5
consecutive days. On Day 1, 3, or 5 after the final injection, the mice were intravenously
administered 300 µg of LTA, bled 2 hours later, and serum TNFα analyzed by ELISA; 1
independent experiment, n=3 mice/group and n=5-7 ELISA wells per group; Day 1, 3 and 5 VC
compared to Pam2Cys: *** = p=0.0002; ** = p=0.004, and p=0.0687, respectively by ANOVA.
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Figure 2-2. Induction of TLR2 tolerance attenuates adoptively transferred EAE.
SJL/J mice were injected intraperitoneally with 29 x 106 PLP139-151-reactive LNC. These mice
were also administered VC or 0.35 µg Pam2Cys intravenously once daily for 5 consecutive days
starting at various times either pre- or post adoptive transfer of the PLP-LNCs. EAE disease
severity was recorded daily for each mouse for 60 days and compiled as a daily mean disease
score for each cohort: (1=tail paralysis, 2=unsteady gait, 3=hind leg paralysis, 4=front leg
paralysis, 5=death). A) Injections were given to recipient SJL/J mice starting at day -2 before cell
transfer and continuing daily for 5 days; 2 independent experiments were performed, one
representative experiment shown, n=4 in each group; p=0.015 by Mann-Whitney. B) Injections
were given to recipient mice starting at day +4 or day +6 before cell transfer and continuing daily
for 5 days; 3 independent experiments were performed, one representative day +4 experiment
shown, n=5 in each group; p<0.0001 by Mann-Whitney. C) Injections were given to recipient
mice starting on day +8 post cell transfer and continuing daily for 5 days; 2 independent
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experiments were performed, one representative experiment shown, n=4 in each group;
p<0.0001 by Mann-Whitney. D) SJL/J mice received VC or 0.35 µg Pam2Cys intravenously on
day +4, +5, and +6 post cell transfer. All mice received 300 µg of LTA intravenously on day +7,
were bled 2 hours later, and serum TNFα analyzed by ELISA; 1 independent experiment
performed, n=8-11 in each group; **** = p<0.0001 by Student’s t test.
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Figure 2-3. The human microbiome-derived product, L654, attenuates EAE.
SJL/J mice injected with PLP-LNCs as in Figure 2 were intravenously administered VC or 5 µg
of L654 daily starting at day +4 after cell transfer and continuing for 5 days. EAE disease
severity was recorded daily for each mouse for 60 days and compiled as a daily mean disease
score for each cohort. 2 independent experiments were performed; one representative experiment
shown, n=5 in each group; p<0.0001 by Mann-Whitney.
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Figure 2-4. Induction of TLR2 tolerance cross-tolerizes to the other TLRs implicated in
EAE pathogenesis.
Naive SJL/J mice were administered VC or 0.35 µg Pam2Cys intravenously for 5 days. A) On
day 6, 40 µg ODN 1668 (a TLR9 ligand) was administered intravenously and serum TNFα was
assayed 1.5 hours later; 2 independent experiments were performed, n=6; **** = p<0.0001 by
Student’s t test. B) On day 6, 60-80 µg R848, (a TLR7/8 ligand) was administered
intraperitoneally and serum TNFα was assayed 1.5 hours later; 1 independent experiment was
performed, n=3; **** = p<0.0001 by Student’s t test.
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Figure 2-5. CNS macrophage CD80-expression, F4/80+CD11c+ cells producing TNFα and
Th17 T helper cells are decreased while splenic Tr1 regulatory T cells are increased after
induction of TLR2 tolerance.
SJL/J mice were injected with PLP-LNCs as in Figure 2 and then intravenously administered VC
or 0.35 µg Pam2Cys daily for 5 consecutive days starting on day +4 post cell transfer. Mice were
sacrificed on day +12 post cell transfer and their spleens and spinal cords harvested and prepared
for flow cytometric analysis. A) Percentage of spinal cord F4/80+ cells that are positive for
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CD80 expression; 2 independent experiments, n=9; * = p=0.0248 by Student’s t test. B)
Percentage of spinal cord F4/80+CD11c+ cells producing TNFα; 4 independent experiments,
n=13; **** = p<0.0001 by Student’s t test. C) Percentage of spinal cord CD4+ T cells that are
positive for IL-17 (Th17 cells); 2 independent experiments, n=7-8; * = p=0.0068 by Student’s t
test gives. D) Percentage of spinal cord CD4+ T cells that are positive for IFNγ (Th1 cells); 2
independent experiments, n=7-8; p=0.8223 by Student’s t test. E) Percentage of spleen CD4+ T
cells that are FoxP3+; 2 independent experiments, n=10; p=0.44 by Student’s t test. F)
Percentage of spleen CD4+ T cells that are CD39+FoxP3+; 2 independent experiments, n=10;
p=0.001 by Student’s t test. G) Percentage of spleen CD4+ T cells that are CD39+; 2
independent experiments, n=10; p=0.1228 by Student’s t test. H) Percentage of spleen CD4+ T
cells are positive for both IFNγ and IL-10 (Tr1 cells); 3 independent experiments, n=13-15; ** =
p=0.0056 by Student’s t test.
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Figure 2-6. Monocytes from progressive MS patients are hyper-responsive to TLR2 stimuli
despite similar expression of TLR2 compared to healthy controls.
Peripheral blood mononuclear cells or monocytes were isolated from blood obtained from
patients with multiple sclerosis or healthy controls. Patients were categorized as progressive and
having currently active disease or relapsing remitting patients and having currently inactive
disease. A & B) Cells were stimulated with vehicle, LPS or MMP at varying doses and TNFα
was measured in the supernatant by ELISA; 4 individual experiments compiled, n=3-6 per
group; *=p=0.01, **=p=0.002, ***=p<0.001. C) TLR2 expression on CD14+ cells was measured
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by flow cytometry; 4 individual experiments compiled, n=3-6 per group. D) TNFα production
per million TLR2 expression CD14+ cells; 4 individual experiments compiled, n=3-4 per group;
*=p<0.05.
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Chapter 3 Lipid 654 Biochemistry and Practical Lessons Learned

Abstract
Lipid 654 (L654) is produced by bacterial species of the Bacteroidetes phylum, which makes up
near 30% of the human gut microbiome. In addition to our finding showing that L654 is present
in the systemic circulation of healthy humans and lower in patients with MS, L654 is also
present in large quantities in the gingival tissue of patients with periodontal disease and in
atherosclerotic lesions in humans. Not only is L654 a microbiome-derived product capable of
accessing human tissues, it is also a Toll-like receptor 2 (TLR2) ligand and so is recognizable to
the immune system. Therefore, L654 is of great interest as a potential mediator of the crosstalk
between the microbiome and the systemic immune system.

As L654 is a newly described molecule, we posited that studying the chemical properties of
L654 would provide insight into its role in human disease. We advanced our techniques used to
isolate, purify and detect L654, along with our abilities to conduct in vitro and in vivo assays
utilizing L654. While interrogating variable biological effects that we observed, we found that
L654 exists in multiple isoforms. Importantly, there is preferential hydrolysis of L654 by
Phospholipase A2 (PLA2) for one isoform into the product Lipid 430 (L430). We have data
suggesting that the ratio of isoforms determines the extent of TLR2 activity, and we have shown
that L430 also has biological activity that is not dependent on TLR2. Synthetic L654 and L430
have not reflected the effects of purified L654 and L430, leading us to believe other factors may
be involved in the observed effects from these purified molecules. Lastly, we have data
suggesting that in serum of patients with multiple sclerosis, there is more breakdown of L654
into L430 compared to in serum from healthy control patients, suggesting a potential role for
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PLA2 in MS. In conclusion, the relationship between L654, L430, and PLA2 is important for
discerning the role of L654 in human disease.

Introduction
We have studied Lipid 654 (L654) throughout the past few years due to our interest in its
potential role in MS(47). Importantly, while L654 originates from the microbiome, it was found
to be present in human tissue and is described as a Toll-like receptor 2 (TLR2) agonist(61, 65,
66). For these reasons, L654 is a candidate for mediating the effects of the microbiome on the
systemic immune response. Working with this lipid, which was recently described by our
collaborator (Dr. Frank Nichols), was not simple and a lot remains to be learned. However,
through trial and error and years of intimate work, we have begun to understand the intricacies of
L654. Our goal throughout this time was to better understand how the chemical properties of
L654 affect its biological properties. Described here is the progression of knowledge gained
through these studies. Most of these details are not publishable; these notions are largely based
on one experiment, incomplete experiments, or mistakes made due to our incomplete
understanding. Yet, this information is important to report so we can continue to build our
knowledge as efficiently as possible.

Results
L654 is produced by bacteria of the Bacteroidetes phylum
L654 is a lipid with a molecular weight of 653.5 g/mole, rounded to 654 for naming purposes. It
is produced in large quantities by many species of the Bacteroidetes phylum of bacteria shown in
Table 3-1. This list is not exhaustive; additional species within this phylum, or other phyla may
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also produce this lipid. This phylum of bacteria composes about 30% of the human gut
microbiome, and much of the periodontal oral microbiome as well. We do not yet know what
function L654 has in the bacteria, though we hypothesize it is a membrane lipid, based on its
hydrophobic properties.

L654 exists in various isoforms
L654 is a lipodipeptide containing two amino acids, serine and glycine, an amide-linked 3hydroxy 17-carbon fatty acid and an ester-linked 15-carbon fatty acid. The 3-hydroxy 17-carbon
fatty acid is isobranched and the 15-carbon fatty acid can be isobranched or anteisobranched(65).
The isobranched 15-carbon fatty acid is depicted in figure 3-1 and is the dominant configuration.
In the isobranched formation, two potential chiral centers exist (asterisks on figure 3-1). In the
case of L654 substituted with anti-isobranched C15:0, an additional chiral center exists.

L654 can be purified by high performance liquid chromatography and identified with multiple
reaction monitoring – mass spectrometry
We derived L654 from Porphorymonas gingivalis (P. ging) – one such Bacteroidetes bacteria
that is easy to grow. To do so, the organism was cultured and a modified Bligh & Dyer lipid
extraction was performed, both as described previously(65). The total lipid extract was purified
by High Performance Liquid Chromatography (HPLC) using a normal phase column and a
neutral mobile phase solvent A (6:8:0.75 hexanes: isopropanol: water). After it was determined
in which fractions the majority of L654 elutes (using multiple reaction monitoring mass
spectrometry [MRM-MS]), those fractions were pooled and re-purified using a normal phase
column and solvent A with 0.1% acetic acid as a mobile phase. At this point the fractions were
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checked for the presence and purity of L654 (using MRM-MS for specificity and Q1-MS for
purity) and it was determined which fractions will be pooled for a final purified L654 batch.

L654 generally elutes near the same time but can vary and its elution does not always correlate
with the absorption spectra at 205 nm. In addition, we have begun to notice that there are earlyand late-eluting fractions of L654 during neutral purification, which may be due to structural
differences like those mentioned above. Some batches may have more of the early-eluting L654
and others may have more of the late. We have recently tested early, middle and late fractions of
our latest batch of L654 in an HEK assay and results suggest that the earliest eluting fraction is
the most TLR2-active L654 (data not shown). Whether the elution time of L654 is associated
with the isoforms present has yet to be determined.

L654 is sonicated in PBS for use in biological assays
After L654 is purified, it is dried in glass tubes or vials at room temperature. L654 is a
hydrophobic lipid and does not naturally solubilize in polar solvents like water or phosphate
buffered saline. We therefore force the lipid into solution by sonicating it for 1 minute to create
micelles that can be evenly dispersed throughout a polar solvent. Previously we have used
dimethylsulfoxide [DMSO] to solubilize L654, which is able to fully solubilize the lipid but also
has unwanted effects on the cells used in our assays (data not shown). We have also utilized
ethanol, cyclodextrin, alkaline phosphatase, and bovine serum albumin as vehicles for
solubilizing L654. These solvents can be vehicles for L654 to some extent in vitro or in vivo and
may have use in future studies (data not shown).
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In the dry form, L654 is stable indefinitely. However, we have had indication that storage in
organic solvents may not be optimal for L654. On the contrary, it seems that we can store L654
in phosphate buffered saline (PBS) for long periods of time without obvious deleterious effects.
Long-term storage at low temperatures likely has little effect on lipids when stored dry or in
micelle form, though if in organic solvent then low temperatures cause aggregation of lipids.

L654 acts as a TLR2 agonist
We have previously published that purified L654 is a toll-like receptor 2 (TLR2) agonist(65);
however, it has become clear that this assertion is more complex than reported. We have shown
using TLR2-deficient mice that serum monocyte chemotactic protein 1 (MCP-1) is increased in a
TLR2-dependent manner 3.5 hours after administration of 1 to 2 µg of L654 (Figure 3-2). We
have learned that intravenous administration leads to more consistent results between mice,
though intraperitoneal administration will also elicit MCP-1 (data not shown). We utilize cellular
assays to screen batches of L654 for TLR2 activity and to study the intricacies of L654 signaling.
These cellular assays have led to our understanding that L654 signaling is more complex than
previously thought, yet these ideas have not been tested in our in vivo MCP-1 assay and so we
cannot comment on their in vivo correlations.

We utilized HEK-293 cells that are transfected with human TLR2, cluster of differentiation
antigen 14 (CD14) and secreted embryonic alkaline phosphatase (SEAP) and which express
endogenous levels of toll-like receptor 1 (TLR1), nucleotide-binding oligomerization domain 1
(NOD1), toll-like receptor 3 (TLR3), toll-like receptor 5 (TLR5), and human toll-like receptor 6
(TLR6). Cells were stimulated for 24 hours with L654 at 1 µg/ml and interleukin 8 (IL-8) was
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measured in the supernatant 24 hours later. With this assay, we have shown that CD14 and TLR2
are required for secretion of IL-8 in response to L654 using blocking antibodies (Figure 3-3);
however, we have seen variation in the requirement for TLR6 and TLR1. In addition to receptor
variability, we see great variability in strength of TLR2 signaling with different batches of L654
(data not shown). We used this HEK assay to screen batches of L654 for optimal TLR2 activity
before use in other studies.

HEK cells often respond differently to L654 than RAW cells or bone-marrow derived
macrophages (BMDMs) (data not shown). Therefore, cell-specific differences may help tease
apart which signaling mechanisms are really necessary to respond to L654, and which additional
mechanisms could modify signal transduction.

Christopher Dietz in Michael Smith’s lab at Storrs produced a synthetic batch of (R)-L654, (S)L654 and a racemic mixture of (R) and (S) L654; however, we have not yet been able to find
TLR2 activity using these synthetic versions of L654 in any assay (Figure 3-4). This finding
leads us to believe that either the ratio of isoforms present or other contaminating lipids play a
role in the observed TLR2 agonist activity of purified L654.

Phospholipase A2 hydrolyses L654 into L430
Dr. Nichols, along with Reza Nemati in Xudong Yao’s laboratory, have shown that calciumdependent recombinant phospholipase A2 (PLA2) can hydrolyze L654 into its component fatty
acid and smaller lipodipeptide that we have named Lipid 430 (L430) by its molecular weight
(Figure 3-5 and 3-6). This has led to many questions but also opened up new avenues for
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examining and explaining our current findings. To start, PLA2 hydrolyzes one isoform of L654
and not the other. We have evidence of this using AB Sciex’s SelexIon device that uses ion
mobility mass spectrometry to differentiate isoforms. We do not know which isoforms are
hydrolyzed, only that with the addition of PLA2 the ratio of one over the other increases (data
not shown). We also have evidence that the batches of purified L654 that are most hydrolysable
by PLA2 are also the ones that show the most TLR2 signaling activity in HEK cells (data not
shown). Adding another level of complexity, L430 possesses biological activity of its own in
some cell lines but not others (61); however, its TLR2 dependence has not been demonstrated.
Christopher Dietz has also produced Synthetic L430, and similar to synthetic L654, it lacks the
biological effects that we have seen with the purified form (data not shown).

Serum from MS patients hydrolyzes L654 into L430 more efficiently than serum from control
patients
PLA2 has been heavily implicated in multiple sclerosis (MS) and we have previously published
that L654 is lower in the serum of MS patients compared to healthy individuals(47, 67-89). To
determine if PLA2 could be playing a role in this finding, labeled 654 was spiked into 6 serum
samples from MS patients and 6 serum samples from control patients and left to incubate in a
buffer containing 10 mM Tris, 2.5 mM CaCl2, 150 mM NaCl and 1% penicillin/streptomycin for
72 hours. Lipids were extracted using an acid extraction and labeled L430 was measured by
MRM-MS. Though not significant, we found more labeled L430 in the serum from MS patients
compared to control patients (Figure 3-7).
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Discussion
There are many questions regarding L654 that are unanswered and unexplored, however, we
have gained much insight into the chemical properties of L654 that can affect the biological
functions we are interested in studying. Functional differences (i.e. activity as a TLR2 agonist) in
L654 batches may be due to the ratio of isoforms or other contaminated lipids present. This may
need to be parsed out using L654 isolated from various species because the variable milieu of
proteins, lipids, and isoforms of L654 may affect TLR2 function. Additionally, the early- and
late-eluting L654 may represent different isoforms of L654. Batch-to-batch variability in earlyand late-eluting L654 may reflect variability in the organism’s growth conditions (i.e. do the
synthetic pathways shunt down different routes depending on the nutrients available and speed of
replication?).

The inactivity of synthetic L654 leads to many questions: Synthetic L654 is only isobranched; is
the ante-isobranched structure important for TLR2 activity? Is there a byproduct in the synthetic
product that is inhibiting the cellular response? Is there a specific (R) to (S) ratio that is needed to
see activity? It is possible that batches of L654 that are not TLR2 agonists are actually TLR2
antagonists, sitting in the receptor without signaling. Lastly, are the presence of other lipids
necessary for facilitating the TLR2 activity of L654? Phosphoglycerol dihydroceramide (PE
DHC) and phosphoglycerol dihydroceramide (PG DHC) are candidates because of our
previously published work, which we now think of as mistaken, claiming PE DHC had TLR2
activity(66). Additionally, PG DHCs elute off of the liquid chromatography column at the same
time as L654, with PE DHCs nearby, and so are almost impossible to perfectly purify away from
one another. This issue is one of the most important and is a priority for future studies.
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Other groups have previously described what seems to be this lipid with some discrepancies in
structure and function, referred to as Flavolipin(90-93). In these studies there are two notable
observations to keep in mind for future studies on L654 function or role in human disease: 1)
Flavolipin was shown to be a novel hemoglutinin which can act as a hemolytic when deacylated
and 2) only the R isoform of the lipid chiral center (the serine chiral center did not make a
difference) was able to elicit inflammatory cytokines in vitro from J771.4, Ba/F transfected with
TLR4 and MD2, and RAW264.7 cell lines – albeit through TLR4 which goes against our studies
thus far(90). Regardless, these concepts may be relevant to the L654 that we study and should be
kept in mind.

Experience dealing with these lipids has afforded us the knowledge that I have attempted to lay
out in this chapter. Though we have a lot left to learn, it is clear that L654 is relevant in human
disease. With our current understanding of L654, we have collaborated in order to study its
relevance in periodontal disease, atherosclerosis, and multiple sclerosis. I will discuss the
relevance of L654 to multiple sclerosis in the next chapter.
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Figures

*)

*)

Figure 3-1. Structure of L654.
Lipid 654 is a lipodipeptide containing two amino acids, serine and glycine, an amide-linked 3hydroxy 17 carbon fatty acid and an ester-linked 15 carbon fatty acid. The 3-hydroxy C17:0 fatty
acid is isobranched and the C15:0 fatty acid can be isobranched or anteisobranched. The
isobranched C15:0 is the dominant form and is depicted in the figure. The asterisks represent
chiral carbons existing in this formation.
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Figure 3-2. Lipid 654 induction of serum CCL2 in mice is dependent on TLR2.
1 µg of Lipid 654 was solubilized in 50% DMSO:water and injected in 100 µl intraperitoneally.
Serum CCL2 levels were measured 3.5 hours later by ELISA; *p<0.01
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Figure 3-3. Purified Lipid 654 induction of IL-8 secretion by HEK293 cells is dependent on
human TLR2, TLR6, and CD14.
An HEK293 cell line transfected with TLR2, MD-2, and CD14 was utilized. Lipid 654 at 1
µg/ml, with or without 10 µg/ml of neutralizing antibody, was incubated with 4.2x104 cells in
10% FBS in DMEM for 24 hours. IL-8 in the supernatant was measured by ELISA; ANOVA
gives ****p<0.0001.
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Figure 3-4. Purified Lipid 654 induces IL-8 secretion by HEK293 while synthetic L654 and
L430 do not.
An HEK293 cell line transfected with TLR2, MD-2, and CD14 was utilized. Purified L654 at 1
µg/ml induces IL-8 from HEK cells but synthetic racemic or (R) and (S) batches of L654 and
synthetic L430 do not. ANOVA gives ****p<0.0001.
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Figure 3-5. PLA2 hydrolysis of L654 into L430.
A) Aliquots of Lipid 654 were hydrolyzed for 4 days with B) porcine pancreatic PLA2 or C)
honey bee venom PLA2. The lipid products were extracted after acidifying the samples with
acetic acid. The lipid products were fractionated by acidic HPLC and analyzed by ESI-MS,
revealing the characteristic three constituent species of Lipid 430 that have been previously
reported in P. gingivalis lipid extracts.
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*)
OH)

Lipid 430

ples of the highly enriched preparation of lipid 654 were subjected to either KOH or NaOCH3 treatment as
nriched lipid 430 (Fig. 1, fraction 39) prepared from the total lipids of P.61
gingivalis was compared with the KOHng MS/MS analysis as described in Materials and Methods. The partial mass spectra are depicted for the m/z 430
total lipids of P. gingivalis (A), NaOCH3-treated lipid 654 (B), or KOH-treated lipid 654 (C). The proposed

Figure 3-6. Structure of Lipid 430.
Lipid 430 is the hydrolyzed product of L654 after release of one fatty acid chain. Lipid 430 has a
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Figure 3-7. MS serum converts L654 to Lipid 430 more efficiently than control serum.
Labeled 654 was spiked into 6 serum samples from MS patients and 6 serum samples from
control patients and left to incubate in a buffer containing 10 mM Tris, 2.5 mM CaCl2, 150 mM
NaCl and 1% penicillin/streptomycin for 72 hours. Lipids were extracted using an acid extraction
and labeled L430 was measured by MRM-MS. MS patient n=6, control patient n=6; MannWhitney gave p=0.23.
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Tables

Oral Bacteroidetes

Gastrointestinal Bacteroidetes

Porphyromonas gingivalis

Prevotella copri

Porphyromonas endodontalis

Parabacteroides merdea

Prevotella intermedia

Parabacteroides distasonis

Tannerella forsythia

Bacteroides fragilis

Capnocytophaga ochracea

Bacteroides vulgatus

Capnocytophaga gingivalis

Bacteroides stercoris

Capnocytophaga sputigena

Bacteroides uniformis

Table 3-1. Commensal oral and gastrointestinal species of Bacteroidetes produce L654.
Bacteria were grown, lyophilized, and extracted for total lipids as described in methods. L654
was detected by MRM-MS.
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Chapter 4 Lipid 654 in Multiple Sclerosis

Abstract
We have previously reported that serum levels of L654 are significantly lower in MS patients
than in healthy controls. Therefore, there is great potential for using L654 as a serum biomarker
for MS disease status or activity, though more studies need to be done to confirm and expand on
this finding. Serum levels of L654 are difficult to quantify using the methods published, making
it impossible to discern differences between populations. We hypothesized that we can address
this issue by increasing the recovery of L654 from serum or by increasing the sensitivity of L654
detection in serum. To do so, we needed to optimize the internal standard used in these studies.
We also planned to create a more practical serum L654 screening test for clinical use. Despite
our best attempts to increase recovery or sensitivity of L654 detection in serum, we have not yet
optimized our method well enough to draw firm conclusions. However, we have obtained
evidence that suggests L654 is indeed lower in the serum of MS patients, and that levels may
correlate with disease activity. Additionally, we have produced an ideal internal standard for use
in future studies. Lastly, we have successfully developed an ELISA screening test for serum antiL654 antibodies, but have not yet obtained a purified monoclonal antibody to L654 that can be
used in an ELISA to detect serum L654.

Introduction
As previously mentioned, we began studying L654 after our preliminary experiments
demonstrated a significant reduction in serum levels of L654 in patients with MS. A receiver
operating characteristic curve developed from this data shows that serum L654 levels can predict
disease status with 94% sensitivity and 92% specificity (data not shown). This led us to two
64

different questions: First, as reported in Chapter 2, what is the relevance of a toll-like receptor
ligand being decreased in the serum of those with an inflammatory disease? Second, can L654 be
utilized as a biomarker for diagnosing MS?

The diagnosis of MS is currently made clinically with the use of the McDonald Criteria, based
on MRI and physical exam findings(2). A definitive diagnosis is often difficult and determining
disease prognosis is not yet possible. Therefore, the addition of a serum biomarker that has
diagnostic or prognostic utility would be instrumental in the ability to provide a definitive early
diagnosis or tailor treatment regimens based on predicted disease severity(2, 94, 95).

L654 is detected and quantified using MRM-MS, as described in the previous chapter. In large
quantities, L654 is easily detectable using the methods that we have published previously(47).
The quantity of L654 found in human serum, however, is extremely low and difficult to detect.
In addition, L654 is extremely “sticky” to both the normal phase high performance liquid
chromatography (HPLC) column used in this procedure as well as to other serum lipids.
Therefore, we have encountered extreme technical difficulty in our attempts to both repeat and
optimize our method for L654 detection and quantification in human serum. Here, I will describe
attempts that we have made thus far, what we found, and what we learned from each.
Additionally, throughout this process we have optimized an internal standard for use during these
studies. An internal standard is an essential requirement for detection by mass spectrometry that
accounts for run-to-run variation inherent in this approach.
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Because the L654 detection protocols that utilized MRM-MS faced numerous technical
difficulties and proved to be suboptimal for clinical diagnostic purposes, we also focused on
producing a monoclonal antibody to L654 for detection in immunologic assays. We therefore
also worked to create an ELISA that would be optimized for detection of anti-L654 antibodies.

Results
Internal standard development
An essential piece of all serum studies was the use of an internal standard. An internal standard is
spiked into each sample in equal amounts, to both control for run-to-run variation in the mass
spectrometer and also to control for any procedural differences in the lipid extraction from
sample to sample. The ideal internal standard is one that has the same chemical properties as
L654 but has a molecular weight that differs enough from L654 to be discerned by MRM-MS.
We began with a limited amount of internal standard that we made using Carbon-13 (13C) carbon
isotopes as one of the carbon sources available to P. ging during its growth(47). When isolated
using our normal protocol for purification of L654, we found L660 (L654 with 6 13Cs
incorporated) with less than 1% contamination with L654. This was utilized as much as possible
before it became contaminated with too much L654, potentially through poor cleaning of caps,
syringes or other tools that are normally washed before re-use. We then worked to make more
internal standard in a similar manner, but had difficulty obtaining an internal standard with at
least 4 molecular mass units difference from L654 for differentiation by MRM-MS. We
substituted a 13C-incorporated version of another bacterial lipid produced by P. ging that we had
obtained in the first attempt, L965, while continuing to work towards a more ideal internal
standard. Eventually, a synthetic L654 had been successfully created and Reza Nemati in
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Xudong Yao’s laboratory was able to perform a chemical exchange using deuterated water and
L654 to create L658. Unfortunately, this molecule proved to be too unstable and extremely
“sticky” resulting in too much carry over from sample to sample during MRM-MS detection to
be useful. Finally, we were able to develop a 13C-incorporated L662 for use as our internal
standard. The studies described here utilize the internal standard that was available to us at that
time. Internal standard is ideally added to serum samples before any manipulation; however, this
is only ideal when the internal standard acts as if it is chemically identical to L654. L660 and
L662 were ideal candidates, yet L660 was not used this way only because we were still in the
midst of our preliminary studies during this time. Therefore, we began adding internal standard
prior to any manipulation of serum samples only once L662 was created.

Attempts to increase L654 recovery using variations to current extraction protocol
Our published method of serum lipid extraction utilized a modified Bligh & Dyer approach(96).
To confirm and extend our finding, we obtained a new set of 59 patient serum samples and
detailed histories (Table 4-1 and 4-2). In running these samples, we found 1) frequent clogging
of the high HPLC column and 2) decreased sensitivity after running about 10 samples. However,
in early run samples before these issues arose, we saw evidence that our initial finding would be
repeatable (Figure 4-1). Unfortunately, if we continued to run samples after cleaning out clogged
columns, we found a drop in sensitivity, making differences in levels of L654 difficult to detect
(Figure 4-2). We attempted to address these issues by performing the same extraction protocol
but leaving behind some of the organic phase to avoid any visible particulates and also by
splitting up our runs between 6 days to avoid a drop in sensitivity. Unfortunately, this neither
stopped the clogging or the decrease in sensitivity seen over time.
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While limited by our knowledge of lipid detection using mass spectrometry left us to defer to
others (Dr. Nichols, Dr. Yao, Reza Nemati and experts at Waters corporation) to troubleshoot the
decreased sensitivity of the machine over time, we focused on attempting to increase recovery of
L654 in our lipid extraction procedure. Due to our findings regarding the role of phospholipase
A2 (PLA2) in breaking down L654 in serum, we hypothesized that multiple uses (freeze/thaws
and sitting at room temperature) of our aliquoted serum could result in enzymatic breakdown and
lower levels of L654 recovered in our lipid extractions. To correct for this or avoid this problem
in the future, we obtained new samples of both serum and plasma. Plasma was derived using
EDTA-lined tubes which would inactivate the calcium-dependent PLA2 that we believe is
responsible for breaking down L654 in serum. However, this did not help increase the amount of
L654 that we were able to detect and plasma samples seemed to be interchangeable with serum
samples after just one thaw (data not shown). Whether this holds true after multiple uses of each
aliquot has yet to be determined.

We attempted two more variations of our previously published method to increase recovery of
L654. The first was to increase the volume of reagents used during extraction while keeping the
ratios the same. To do this we increased our working volume of serum by adding water to reach
the desired volume. The second variation we attempted was to let the serum incubate in
chloroform: methanol (1:2, v:v) overnight (instead of 30 minutes) in the hopes of fully isolating
L654 from any polar binding proteins, if we were not doing so in our normal extraction
procedure already. Neither of these variations increased our recovery of L654 from serum
samples (data not shown). Throughout all of these attempts to increase L654 recovery, we were
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still incurring issues with clogging of the HPLC column. Dr. Jeff McDonald at UT Southwestern
suggested the next method described here to eliminate issues with clogging.

Attempts to decrease clogging of HPLC by pre-separating proteins
Dr. McDonald’s method was adjusted for lipid derivation using 200 µl of serum. A mixture of
1:1 (v:v) dichloromethane: methanol was added to a glass tube containing 200 µl of serum and
vortexed. Next, the mixture was spun down for 5 minutes at 2000 rpm in a swinging bucket
centrifuge. The supernatant was decanted into a new glass tube for further extraction. The pellet
containing serum proteins was discarded, and 3 ml of calcium/magnesium free phosphate
buffered saline (PBS) was added to the tube containing the supernatant and vortexed. The
mixture was spun down for 5 minutes at 2000 rpm in a swinging bucket centrifuge. The lower
layer containing the organic fraction was removed and placed into a new glass vial to let dry
down overnight. The vials at this stage were analyzed for L654 by MRM-MS.

We used this method in three different tests. In our first and largest test run we analyzed 59
serum samples, adding L965 internal standard after derivation. Although the sensitivity was still
low, we did not encounter any clogging for the first time. Importantly, and also for the first time,
we noticed a stratification of our data by MS disease status. Those with a progressive disease
status had significantly lower levels of L654 compared to those with relapsing remitting disease
(Figure 4-3). In addition, those patients with relapsing remitting disease that had recent flares
also had low levels of L654. However, our initial finding of decreased serum L654 in all MS
patients did not repeat when using this method. Therefore, we developed a new interest in the
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protein carrier responsible for transporting L654 in the serum, and the potential change in
activity status of L654 in its free versus bound form.

Our next two tests using this method were performed using serum or plasma with 21 patient
samples each. For these tests we added 662 internal standard before any manipulation of serum
or plasma. We ran the serum samples ourselves and sent the plasma samples to Waters
Corporation, who had developed their own method for detection of L654 in serum lipid samples.
In both of these attempts, the sensitivity of detection or recovery of L654 was too low to
confidently analyze the data. When we tried to analyze, we did not see any differences in MS
and controls or between active and inactive disease status (data not shown).

Using our current methods for L654 detection by MRM-MS, we do not have a large separation
in elution times between L654 and other serum lipids. One reason the sensitivity of L654
detection may be low is due to ion suppression from lipids eluting simultaneously. The next two
lipid extraction protocols were attempted for the purpose of decreasing the amount of other
serum lipids while still retaining all of the L654 in our samples.

Attempts to increase sensitivity of L654 detection using acidic serum lipid extraction and onestep purification
We attempted an acidic version of our normal lipid extraction procedure in order to decrease the
other serum lipids that were being forced into the organic fraction with L654. In this method, we
added 1 ml of deionized water, 100 µl of glacial acetic acid, and 2 ml of chloroform to 300 µl of
serum. The mixture was vortexed and spun down for 10 minutes at 2000 rpm. The lower organic
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phase was removed and placed into a new vial to dry down overnight. These samples were then
analyzed by MRM-MS for levels of L654. Utilizing this method, we determined that while we
reduced the extraneous lipid content in our fraction for analysis, we also had less L654 and so
this was not an improvement to our current methods (data not shown).

In another attempt to separate L654 from other serum lipids to increase detection sensitivity, we
performed our normal extraction procedure followed by a one-step purification by HPLC before
analyzing the samples by MRM-MS for levels of L654. In this method the 662 IS was added
before any manipulation of serum samples. We utilized this method twice, first with 59 serum
samples and then with 20 serum samples. In both runs, we saw 1) increased sensitivity of L654
detection and 2) a trend towards decreased L654 in MS patients compared to controls, though not
reaching significance (Figure 4-4).

Development of an ELISA for detection of L654 antibodies
Through much trial and error, the following enzyme-linked immunosorbent assay (ELISA)
protocol was developed for the purpose of detecting anti-L654 antibodies. While we worked
towards producing a monoclonal antibody to L654, we utilized Lipid A and an IgM or IgG antiLipid A monoclonal antibody to develop an ELISA protocol that is optimized for detection of
lipids. As our positive control for L654, we utilized mouse serum from a mouse that was
successfully immunized to L654.

All reagents were brought to room temperature before use in this ELISA. A solution of 8 µg/ml
of lipid-free bovine serum albumin (BSA) was plated at 100 µl per well overnight at 4 degrees
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Celsius. After the plate was brought to room temperature, it was washed 4 times with >300 µl
per well of PBS. 8 µg of Lipid A vortexed in 100 µl of PBS or 8 µg of L654 sonicated in 100 µl
of PBS was plated in each well for 1 hour. At this point, the plate was tapped dry but not washed.
The wells were then blocked with 300 µl of PierceTM Protein-Free (PBS) Blocking Buffer for 2
hours. The plate was then tapped dry but not washed. At this point sample containing mouse
anti-Lipid A or potential anti-L654 antibodies (serum or supernatant) was added at 100 µl per
well for 2 hours. The plate was washed 4 times with >300 µl per well of PBS. Either Goat AntiMouse IgM (µ-chain specific) Peroxidase antibody or goat Anti-Mouse IgG (Fc specific)
Peroxidase antibody was added in 100 µl per well for 1 hour. The plate was washed 4 times with
>300 µl per well of PBS. ABTS® ELISA HRP Substrate was added at 100 µl per well for 1 hour
in the dark. The plate was stopped using 100 µl per well of ABTS® Peroxidase Stop Solution
and read at 405 nm. This protocol works well with Lipid A, and seemed to work with L654 when
tested using mouse serum immunized to L654 as a positive control (Figure 4-5). Before we can
modify this ELISA protocol for detection of serum L654, however, we must produce a
monoclonal antibody that is specific to L654.

Methods attempted to develop a monoclonal antibody to L654
Due to technically difficulties with MRM-MS, creating a monoclonal antibody to L654 was very
important to our future studies. We initially tired to find a solvent that would solubilize L654 as
well as a peptide, so that we could conjugate them together. However, we were unable to find
such a solvent. We therefore tried utilizing micelles made by sonicating L654 in PBS to
immunize a mouse to L654.
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In our first attempt at this, we immunized four BALB/c mice with micelles containing 750 µg of
L654 and 25 µg of Lipid A, which we were hoping would act as a stronger adjuvant than L654.
Sonicating these lipids together in PBS should form micelles without the addition of other fatty
acids. After the first immunization, the mouse was boosted every 10-20 days for a total of 7
boosts before sending one spleen to Precision AntibodyTM for hybridoma production. In this
case, the serum of the immunized mice clearly showed a propensity for IgM antibodies that
bound to L654 in our ELISA described above. In hopes to find a single hybridoma that was
specific to L654, we screened sups from hundreds of hybridoma clones. We could not find a
hybridoma that only bound to L654 and not Lipid A or another lipid that was tested (Figure 4-6).
In another attempt we repeated the immunization strategy that we used in our first approach, but
only boosted with L654 to try to increase the production of B cells specific to L654.
Additionally, we sent the spleen after only 2 boosts as we saw the best response in the serum at
that point in our last study. Unfortunately, we were still unable to find a hybridoma that did not
bind to other lipids as well.

Because the hybridomas formed in the first fusion attempts were all IgM producers, we tried to
focus on production of an IgG response in the hopes that specificity would increase with this
isotype. We approached this with 4 different strategies. First, we utilized a similar micelle
approach but without Lipid A, so as to avoid non-specific binding, and instead with 100 µg of
myelin oligodendrocyte glycoprotein (MOG) in the micelle. The rationale underlying this
approach was that a peptide in close proximity with L654 could potentially yield a better
IgG response. The serum from this mouse was never promising enough to send the spleen for
fusion, as we did not see evidence of an IgG response.
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The next strategy was to solubilize L654 in a solution of 10 µg/ml of BSA before sonicating to
create micelles. Because our ELISA results suggested that BSA was able to bind to L654, we
hoped this might yield an IgG response to L654. We were unsuccessful in this endeavor (data not
shown). Next, we immunized a mouse with 500 µg of lipid in 10 µg/ml of BSA emulsified with
600 µg Complete Freund’s Adjuvant (CFA). We boosted the mouse with only L654 emulsified
with incomplete Freund’s Adjuvant (IFA). The serum from this mouse never yielded the IgG
response we were looking for and so the spleen was not sent for fusion (data not shown).

Lastly, we tried a new method to conjugate L654 to a peptide. We attempted to use click
chemistry (using DBCO-Sulfo—NHS ester to link to L654 and Azido-PEG4-NHS ester to link
to keyhole limpet hemocyanin [KLH]) to conjugate L654 to KLH, but we were not successful
(data not shown). Instead of successfully immunizing a mouse to L654, we next wanted to screen
existing phage display libraries for binding to L654. We planned to do so with AxioMx Inc but
their normal protocol still required L654 to be bound to a small peptide. We worked with them to
instead try our developed ELISA method of L654 bound to BSA and allowed them to use our
developed ELISA protocol described above. Unfortunately, the controls for their screen did not
work with our ELISA protocol. We tried one last attempt to link L654 to a protein, biotin,
ourselves using EZ-LinkTM Amine-PEG11-Biotin, but we were unsuccessful (data not shown).

Discussion
Detecting and quantifying serum L654 is fraught with many difficulties. Although we continue
working to confirm our initial finding that L654 is decreased in the serum of MS patients, we
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have seen some evidence that confirms total L654 is decreased in MS patients. Additionally, we
have data suggesting that when protein is removed from the serum, L654 is decreased only in
patients with active disease. Therefore, our working hypothesis is as follows: the majority of the
total stores of L654 (protein-bound) are lower in all MS patients compared to controls for
unknown reasons (decreased production by the microbiome, decreased transport across the gut
epithelium, etc); however, only the free form of L654 is decreased during active MS (potentially
due to increased breakdown of only the free form of L654 by PLA2, implicated in active
disease). Currently, we are still working to find an ideal method for L654 detection and
simultaneously working towards isolating the protein carrier responsible for serum transport of
L654. Identifying the protein carrier could be used to pull-down and then quantify L654 in a
much cleaner matrix. We are currently looking into the possibility of high-density lipoprotein
(HDL) as a carrier for L654.

While we have successfully developed an ELISA screening test for anti-L654 antibodies, we rely
on the ability to conjugate L654 to a peptide for development of a monoclonal antibody. We
therefore have requested the help of Christopher Dietz in Dr. Michael Smith’s laboratory, who
has already chemically synthesized L654. He is currently working to chemically link L654 to
biotin.

At this point, we have learned a great deal in our attempts to both analyze L654 in serum as well
as create a more practical screening tool for future use. The most pressing future studies should
be to determine the protein(s) that carries L654 in human serum. This knowledge can be used to
make selective isolation of L654 for detection much more efficient and clean of other serum
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lipids that are be masking the detection of L654. Additionally, as soon as we synthetically link
biotin to L654, developing a monoclonal IgG antibody to L654 by immunization or finding a
specific protein-binding molecule through screening an existing phage display library becomes
much more likely. With the use of an anti-L654 monoclonal antibody, we have the potential to
bypass all difficulties with MRM-MS and simply utilize an ELISA to detect and quantify serum
L654.
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Figure 4-1. MRM-MS analysis of L654/Lipid 660 before clogging of HPLC.
Initial analysis of the absolute ion abundance of L654/Lipid 660 by MRM-MS showed that MS
patients have less L654 in serum compared to control patients. MS patient n=6, control patient
n=3; Wilcoxon rank-sum gave p=0.04.
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Figure 4-2. MRM-MS analysis of L654/Lipid 660 over time.
A) Initial analysis of the absolute ion abundance of L654/Lipid 660 by MRM-MS showed the
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Figure 4-3. MRM-MS analysis of L654/Lipid 965 when serum proteins are removed before
lipid extraction.
Protein was removed before lipid extraction as described in methods. MRM-MS analysis of
L654/internal standard showed no difference between serum L654 of control patients and
patients with relapsing remitting MS, while patients with progressive MS showed significantly
lower levels of L654 compared to both control patients and relapsing remitting MS patients.
Control patient n=22, RRMS patient n=24 , progressive MS patients (including PPMS and
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Figure 4-4. MRM-MS analysis of L654/Lipid660 after one-step purification.
Serum lipid extracts were each purified by HPLC and early eluting lipids were discarded.
Remaining fractions were pooled and analyzed by MRM-MS. Control patient n=23 , MS patient
n=29; Wilcoxon rank-sum gave p=0.59.
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Figure 4-5. ELISA development for detection of lipid antibodies.
The ELISA protocol described was followed using anti-Lipid A antibodies as a control and
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Supernatants were tested for ability to bind L654, two bacterial lipids (P. ging
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Tables
Age
51
44
50
63
50
58
65
63
60
63
60
46
42
24
54
48
42
41
51
40
46
32
34
31

Gender
Female
Female
Female
Male
Female
Female
Female
Female
Female
Female
Female
Female
Female
Male
Male
Female
Male
Male
Female
Female
Male
Female
Female
Female

Family History of MS
None
None
None
None
None
Two first cousins have MS
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None

Table 4-1. Second control cohort.
Control patients were consented, and detailed histories were taken. Shown are the general
demographics and family history of MS in this cohort.
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Family Antibiotic Age at
History use in last diagno
of MS
year
sis

Age

Gender

49
50
54
74
52
55
34
66
36
49
65
37
47
25
40
63
59
48
37
37
49
65
60
35
44
47
49
36

Male
Female
Female
Female
Female
Female
Male
Female
Female
Female
Female
Female
Female
Female
Male
Female
Female
Female
Male
Female
Female
Female
Female
Female
Female
Female
Female
Female

No
No
Yes
Yes
No
No
No
Yes
No
No
Yes
No
Yes
Yes
No
No
No
Yes
No
Yes
No
Yes
No
Yes
Yes
No
No
No

Yes
Yes
No
Yes
No
Yes
No
No
No
Yes
Yes
No
Yes
No
Yes
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
Yes
Yes

46
25
47
46
45
38
24
16
29
28
51
26
38
18
26
53
52
44
37
34
34
43
40
24
31
30
40
28

49
49
55
68
49
49

Male
Male
Female
Male
Female
Female

No
No
Yes
No
Yes
No

Yes
No
No
Yes
No
No

38
49
47
57
26
28

57

Male

No

Yes

41

Clinical subtype
Relapsing Remitting/
Secondary progressive
Secondary Progressive
Relapsing Remitting
Slowly Progressive
Relapsing Remitting
Secondary Progressive
Relapsing Remitting
Stable MS
Relapsing Remitting
Relapsing Remitting
Primary Progressive
Relapsing Remitting
Relapsing Remitting
Relapsing Remitting
Relapsing Remitting
Relapsing Remitting
Relapsing Remitting
Relapsing Remitting
Relapsing Remitting
Relapsing Remitting
Relapsing Remitting
Secondary Progressive
Slowly Progressive
Relapsing Remitting
Relapsing Remitting
Relapsing Remitting
Relapsing Remitting
Relapsing Remitting
Relapsing Remitting/
Secondary progressive
Relapsing Remitting
Relapsing Remitting
Secondary Progressive
Relapsing Remitting
Relapsing Remitting
Relapsing Remitting/
Secondary Progressive

Time since
diagnosis

Current MS Tx

Recent exacerbation (<2
years)

3 years
25 years
7 years
28 years
7 years
17 Years
10 years
50 years
7 years
21 years
14 years
11 years
9 years
7 years
14 years
10 years
7 years
4 years
1 week
3 years
15 years
23 years
20 years
11 Years
13 Years
17 Years
9 Years
8 Years

Teriflunomide
Cytoxan and IV steroids
Avonex
Avonex
Tysabri
Cellfate
Gilenia
Copaxone
None
Gilenia
Alternative Tx
Tecvidera
Avonex
None
Azathioprine
Avonex
Tysabri
Rebiff
None
Copaxone
Tysabri
Tysabri
None
Avonex
Copaxone
Tecvidera
Gilenia
Rituxin

Recent
None
None
None
None
None
None
None
None
None
None
Recent
None
None
Recent
None
None
Recent
Recent
None
Recent
None
None
None
None
None
Recent
Recent

11 Years
6 months
8 Years
1 year
23 Years
21 Years

Copaxone
Tecvidera
Avonex
None
Tecvidera
Tysabri

None
Recent
Recent
None
None
None

16 years

Copaxone

None

Table 4-2. Second MS cohort.
MS patients were consented, and detailed histories were taken. Shown are the general
demographics, family history of MS, antibiotic use, MS subtype, treatment and history of MS
disease course in this cohort.
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Chapter 5 Future Directions and Synthesis
Future Directions
Defining the mechanism of EAE attenuation by TLR2-induced Tolerance
Through TLR tolerance induction, we have shown that TLRs must be contributing to the disease
pathogenesis of adoptively transferred EAE. Among the potential TLRs involved are TLR2,
TLR7 and TLR9 because we determined that signaling through any of theses TLRs was inhibited
utilizing our 5-day tolerance induction protocol. While this indicated to us that a treatment
modeled after this induction protocol would therefore be an efficient way to tolerize to multiple
TLRs simultaneously, it brings up further questions regarding which TLRs are necessary,
sufficient, and contributory to the disease pathogenesis of EAE.

In addition, after TLR tolerance induction, multiple cellular changes were observed. Reflective
of tolerance, CD80-expression on CNS and splenic macrophages was decreased. An interesting
population of F4/80+CD11c+ cells producing TNFα was significantly decreased in tolerized
mice. These cells have not yet been described in EAE, and determining their role will be a topic
of future study. Additionally, the proportion of Th17 T cells infiltrating the CNS was decreased
in tolerized mice. This is particularly interesting because as of yet there is no known mechanism
for TLR2-induced inhibition of already differentiated Th17 cells, though the vast majority of
transferred PLP-specific T cells in our model are already differentiated. Lastly, we found an
increase in splenic Tr1 regulatory cells. We do not know if these Tr1s are induced from the
recipient or donor T cells, and whether they are PLP-specific or capable of suppressing the
transferred encephalitogenic T cells. However, Tr1 regulatory cells are particularly suppressive
to Th17 cells and so could be responsible for inhibiting the trafficking of the Th17 cells from the
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spleen to the CNS. We plan to determine the relevance of each of these cellular associations to
determine which are responsible for the observed disease attenuation.

After TLR tolerance induction in EAE, we observed two separate effects on disease: delay of
onset and chronic attenuation. We believe we can even separate these effects by starting
tolerance induction at different time points in relation to transfer of LNCs. If this is true then
separate cellular mechanisms may be accountable for each effect, and understanding this can be
extremely important in translating our findings to treatment of MS.

Defining the mechanism of TLR2 hyper-responsiveness in monocytes from MS patients
We observed the TLR2 hyper-responsive phenotype of monocytes from patients with active or
progressive MS. We first plan to increase the sample size of this study and conduct a more
thorough association analysis of disease status and severity with TLR2 hyper-responsive
monocytes. Importantly, two hypotheses can explain this phenotype: 1) MS patients are deficient
in TLR tolerance-inducing ligands like L654 and 2) Monocytes from MS patients have a
deficiency in the ability to become TLR tolerized. While we continue our analysis of serum
L654, we address the first potential hypothesis. Attempting to tolerize monocytes from MS
patients can directly test the second hypothesis. Additionally, assessing the expression of known
TLR signal regulating molecules in monocytes from MS patients can contribute to our
knowledge of whether a defect exists or whether these proteins are simply not being induced in
vivo. Determining which, if any, hypothesis is correct would guide future studies attempting to
correct or treat this deficit in MS patients.
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Determine which factors contribute to the TLR2 activity of L654
While utilizing L654 in vivo and in vitro reflects TLR2 activity and is repeatable if the same
batch of lipid is used throughout the studies, it would be extremely beneficial for future studies
to understand the factors that contribute to the variability in the batch-to-batch TLR2 activity and
the lack of TLR2 activity in synthetic batches of L654. Among the possibilities that must be
tested, the ratio of L654 isoforms remains one of the top candidates. This can be tested
empirically by determining the ratio of isoforms present in various batches of L654 and then
correlating the ratio to TLR2 activity in HEK assays. This can also be determined utilizing
synthetic (R)- and (S)-L654 in different ratios to stimulate HEK cells and measure TLR2
activity. If the various isoforms prove to play a role in the TLR2 activity of L654 then we must
also assess the role of PLA2 in the in vivo and in vitro cellular responses to L654, as PLA2
hydrolyses one isoform of L654 but not others.

Next, contaminating lipids in purified batches of L654 may be necessary for TLR2 activity. This
can be assessed in a similar manner, by determining which lipid species are present in each
purified batch of lipid and correlating that to TLR2 activity or by adding single lipids to synthetic
batches of L654 to determine which increases the TLR2 activity in HEK assays.

Lastly, the variation in response to L654 based on cell type requires further inquiry. Cell-specific
enzymes, like PLA2, varying co-receptor expression, and differing endocytic or phagocytic
properties may be determinants in the ability of cells to respond to L654. These hypotheses can
be addressed utilizing blocking reagents. Determining the factors that contribute to the TLR2
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activity of L654 would not only increase the efficiency of future studies, but would also provide
invaluable information for determining the relevance and function of L654 in MS.

Determine the role and relevance of such a role for PLA2 in the breakdown of L654 in MS
PLA2 has been heavily implicated in both MS and EAE. These studies are controversial, most
likely due to varying tissues analyzed, read-outs of PLA2 expression or activity, and PLA2
isoforms studied. However, because we have shown that PLA2 can hydrolyze L654 and that
L654 is decreased in the serum of MS patients, the possibility that PLA2 is contributing to this
finding must be addressed. To start, studying the breakdown of labeled L654 that has been
spiked into serum samples from MS and control patients should be repeated and expanded. In
addition, in our own hands, we would like to study PLA2 activity in MS and control tissues.

Determining this is important for the translatability of our findings regarding TLR tolerance
induction. Administering L654 to patients would not be efficacious if MS patients have increased
PLA2 activity that leads to the breakdown of L654. In that case, however, administration of a
synthetic version or another TLR2 ligand that is not broken down by PLA2 can be utilized, or
perhaps treatment with a PLA2 inhibitor is the better option.

Determine if and how L654 can be utilized as a biomarker for MS
Based on our findings thus far, serum levels of L654 seem to allow for differentiation of MS
patients from healthy controls and also patients with Alzheimer’s disease. With our current
technical difficulties, we have still seen evidence that this finding will be repeatable. In addition,
when protein was removed from serum samples prior to lipid extraction, our initial finding was
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not repeatable; however, the protein-free portion of L654 seemed to decrease in relation to
disease activity. However, we must conduct a larger study to repeat both findings and also a
longitudinal study to determine if these findings are consistent over time or if it changes with
disease course. This will allow us to determine how and when L654 can be utilized as a
diagnostic or screening test for MS.

If these studies are confirmed to be consistent over time in MS patients, serum levels of L654
may be used as an objective diagnostic test for MS. Such a biomarker may aid in early diagnosis
and therefore allow for earlier treatment interventions. Additionally, if findings from this study
indicate that L654 levels are significantly different from controls at even the earliest stages of
MS, then there is also potential for serum L654 to be used as a screening test for MS in at risk
populations (such as family members of MS patients). Alternatively, if levels fluctuate in
correlation with disease activity, severity or MS subtype, then serum L654 may have utility as a
prognostic marker to guide treatment regimens.

Determine the identity and role for a L654 protein carrier in trafficking, TLR2 activity and
correlation with MS disease activity
Of the most pressing future studies is to determine the protein-carrier for L654 in serum. In
doing so, we are 1) furthering our knowledge of L654 and its in vivo role, 2) opening up a new
door for functional testing studies to determine if bound or unbound L654 has greater TLR2
activity and 3) offering a potential new way to isolate L654 from serum by first isolating its
protein-carrier. This last point would help us to avoid clogging while running serum samples on
HPLC, perhaps increase the sensitivity of the machine by cleaning up the surrounding matrix and
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allow us to confirm our findings regarding L654 in serum. Based on our preliminary findings,
decreased serum free L654 may correlate with MS disease activity and therefore may be the
TLR2 active fraction of L654. Therefore, studying the TLR2 activity of free versus bound L654
would aid in our understanding of its in vivo function. Identifying a protein carrier would also
allow us to begin studying the trafficking and absorption pattern of L654 without obtaining a
monoclonal antibody to L654. Understanding this would be essential when attempting to
translate these findings to treatments for patients with MS.

Synthesis
While much effort is made to study potential differences in the microbiome on a species-basis,
there are very few studies addressing the microbiome-products that might mediate the observed
effects on the systemic immune system. It is conceivable that there is no change in microbiome
make-up but only in what the microbiome is producing or in the selective absorption of products
by the host. We regard L654 as a representative microbiome product that gains access to the
systemic circulation and is capable of communicating with the immune system through pattern
recognition receptors, and we imagine that there are many other microbiome-derived PAMPS
that may play similar roles. We hope that this work highlights the significance of these concepts
and the need for further investigation of these topics.

This body of work suggests that microbiome-derived PAMPS that gain access to the system
circulation, such as L654, may play an important role in MS. Through proof of concept studies
we offer one such potential mechanism of L654-mediated immune regulation that may be
deficient in MS patients. We simultaneously offer a potential new therapeutic approach to the
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treatment of this disease. Additionally, we now have improved abilities to purify and detect L654
as well as utilize this molecule in vitro and in vivo. Though complexities have yet to be resolved,
we have increased our overall understanding regarding the interaction of L654 with the innate
immune system as a TLR2 agonist. In addition, we have shown that L654 may have utility as a
biomarker for disease status or activation in MS.

Our overall working hypothesis is that a homeostatic role exists for microbiome products that
enter the system circulation. Tonic, low-level interaction of PAMPS with TLRs can set the
threshold and magnitude of successive signaling through TLRs. When maintained at homeostatic
levels, the balance between inflammation and immune regulation remains; however, if a
deficiency in these microbiome-derived PAMPS exists, and cells are not TLR tolerized, they
become hyper-responsive to TLR ligation. The balance between immune regulation and
inflammation is tipped towards inflammation in this scenario, which can contribute to the
development of autoimmunity (Figure 5-1).
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Figure 5-1. Synthesis of working hypotheses.
PAMPS that gain access to the systemic circulation like L654 can have tonic interaction with
TLRs. This continual, low-level TLR signaling may set the rheostat for successive TLR
signaling at homeostasis. When this regulatory mechanism is disrupted due to decreased PAMP
absorption, increased breakdown or sequestration of PAMPS in the systemic circulations, then
successive TLR signals could lead to hyper-responsiveness and excessive inflammation. Tilting
the balance towards inflammation in this way can contribute to the etiology of an autoimmune
disease like MS. Depicted in the figure are the various stages of the hypothesized MS disease
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pathogenesis and in red writing it is noted how our findings may contribute to this process if
TLR tolerance is deficient.
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